WO1996032149A1 - Pulmonary delivery of aerosolized medicaments - Google Patents

Pulmonary delivery of aerosolized medicaments Download PDF

Info

Publication number
WO1996032149A1
WO1996032149A1 PCT/US1996/005070 US9605070W WO9632149A1 WO 1996032149 A1 WO1996032149 A1 WO 1996032149A1 US 9605070 W US9605070 W US 9605070W WO 9632149 A1 WO9632149 A1 WO 9632149A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
pharmaceutical
dry powder
particle size
effective amount
Prior art date
Application number
PCT/US1996/005070
Other languages
French (fr)
Inventor
Robert M. Platz
John S. Platton
Linda Foster
Mohammed Eljamal
Original Assignee
Inhale Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23679173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996032149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX9707855A priority Critical patent/MX9707855A/en
Priority to JP8531213A priority patent/JPH11503731A/en
Priority to EP96911738A priority patent/EP0825885B1/en
Priority to AT96911738T priority patent/ATE261742T1/en
Priority to CA002218116A priority patent/CA2218116C/en
Priority to AU54827/96A priority patent/AU702150B2/en
Priority to DE69631881T priority patent/DE69631881T2/en
Application filed by Inhale Therapeutic Systems filed Critical Inhale Therapeutic Systems
Priority to US08/733,225 priority patent/US6258341B1/en
Publication of WO1996032149A1 publication Critical patent/WO1996032149A1/en
Priority to US08/950,385 priority patent/US6309671B1/en
Priority to US08/951,312 priority patent/US6019968A/en
Priority to US09/531,183 priority patent/US6514496B1/en
Priority to US09/879,853 priority patent/US6589560B2/en
Priority to US10/413,016 priority patent/US20030215512A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Definitions

  • the present invention relates generally to methods and compositions for the dry powder formulation of pharmaceuticals, including macromolecules, for pulmonary delivery.
  • pulmonary delivery a drug dispersion for oral inhalation
  • Such pulmonary drug delivery compositions are designed to be delivered by inhalation by the patient of a drug dispersion so that the active drug within the dispersion can reach the lung. It has been found that certain drugs delivered to the lung are readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery is particularly promising for the delivery of macromolecules (proteins, polypeptides and nucleic acids) which are difficult to deliver by other routes of administration. Such pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
  • Pulmonary drug delivery can itself be achieved by different approaches, including liquid nebulizers, aerosol-based metered dose inhalers (MDI's), and dry powder dispersion devices.
  • Aerosol-based MDI's are losing favor because they rely on the use of chlorofluorocarbons (CFC's), which are being banned because of their adverse effect on the ozone layer.
  • Dry powder dispersion devices which do not rely on CFC aerosol technology, are promising for delivering drugs that may be readily formulated as dry powders. Many otherwise labile macromolecules may be stably stored as lyophilized or spray-dried powders by themselves or in combination with suitable powder carriers. The ability to deliver pharmaceutical compositions as dry powders, however, is problematic in certain respects.
  • the dosage of many pharmaceutical compositions is often critical so it is necessary that any dry powder delivery system be able to accurately, precisely, and reliably deliver the intended amount of drug. Moreover, many pharmaceutical compositions are quite expensive. Thus, the ability to efficiently deliver the dry powders with a minimal loss of drug is critical. It is also essential that the powder be readily dispersible prior to inhalation by the patient in order to assure adequate distribution and systemic absorption.
  • a particularly promising approach for the pulmonary delivery of dry powder drugs utilizes a hand-held device with a hand pump for providing a source of pressurized gas.
  • the pressurized gas is abruptly released through a powder dispersion device, such as a venturi nozzle, and the dispersed powder made available for patient inhalation.
  • a powder dispersion device such as a venturi nozzle
  • the dispersed powder made available for patient inhalation.
  • hand-held devices are problematic in a number of other respects.
  • the particles being delivered are less than 10 ⁇ m in size, usually in the range from l ⁇ m to 5 ⁇ m, making powder handling and dispersion more difficult than with larger particles.
  • the problems are exacerbated by the relatively small volumes of pressurized gas, which are available using hand-actuated pumps.
  • venturi dispersion devices are unsuitable for difficult-to-disperse powders when only small volumes of pressurized gas are available.
  • Another requirement for hand-held and other powder delivery devices is efficiency. It is important that the concentration of drug in the bolus of gas be relatively high to reduce the number of breaths required to achieve a total dosage.
  • the ability to achieve both adequate dispersion and small dispersed volumes is a significant technical challenge that requires in part that each unit dosage of the powdered composition be readily and reliably dispersible.
  • a dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 ⁇ m mass median diameter (MMD), usually 1.0-4.0 ⁇ m MMD, and preferably 1.0-3.0 ⁇ m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 ⁇ m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 ⁇ m MMAD, and preferably 1.5-4.0 ⁇ m MMAD.
  • Such compositions are of pharmaceutical grade purity.
  • the present invention is based at least in part on the dispersibility characteristics of the pharmaceutical-based dry powder compositions produced according to the present invention.
  • the dispersibility characteristics of the subject pharmaceutical-based compositions means that they are more suitable for use in pulmonary delivery devices than compositions prepared by other methods.
  • the compositions of the invention are readily aerosolized and rapidly absorbed through the lungs of a host when delivered by a dry powder inhaler.
  • the term "dispersibility” or “dispersible” means a dry powder having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 ⁇ m mass median diameter (MMD) , usually 1.0-4.0 ⁇ m MMD, and preferably 1.0-3.0 ⁇ m MMD; a delivered dose of about >30%, usually > 40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 ⁇ m mass median aerodynamic diameter (MMAD) , usually 1.5-4.5 ⁇ m MMAD, and preferably 1.5-4.0 ⁇ m MMAD.
  • MMD mass median diameter
  • MMAD aerodynamic diameter
  • the term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli.
  • the powder is said to be “respirable.
  • the average particle size is less than about 10 microns ( ⁇ m) in diameter with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 ⁇ m and most preferably less than about 5.0 ⁇ m.
  • the particle size distribution is between about 0.1 ⁇ m and about 5 ⁇ m in diameter, particularly about 0.3 ⁇ m to about 5 ⁇ m.
  • dry means that the composition has a moisture content such that the particles are readily dispersible in an inhalation device to form an aerosol.
  • This moisture content is generally below about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w.
  • terapéuticaally effective amount is the amount present in the composition that is needed to provide the desired level of drug in the subject to be treated to give the anticipated physiological response. This amount is determined for each drug on a case-by-case basis. Guidelines are given hereafter.
  • physiologically effective amount is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each drug and its ultimate approved dosage level. Guidelines are given hereafter.
  • pharmaceutically acceptable carrier means that the carrier can be taken into the lungs with no significant adverse toxicological effects on the lungs.
  • One aspect of this invention is a dispersible pharmaceutical-based dry powder composition for pulmonary delivery, the composition comprising a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
  • compositions of this invention have a suitable for pulmonary delivery because of their dispersibility characteristics. Such compositions were not previously known in the art.
  • the pharmaceutical In the dry state, the pharmaceutical may be in crystalline or amorphous form.
  • Some examples of pharmaceutical compositions suitable for formulation into dispersible dry powders are listed in Table 1. These include macromolecule and non-macromolecule-based pharmaceuticals, usually macromolecules, with insulin, interleukin-1 receptor, parathyroid hormone (PTH-34) , alpha-1 antitrypsin, calcitonin, low molecular weight heparin, heparin, interferon, and nucleic acids being preferred.
  • a therapeutically effective amount of active pharmaceutical will vary in the composition depending on the biological activity of the drug employed and the amount needed in a unit dosage form. Because the subject compounds are dispersible, it is highly preferred that they be manufactured in a unit dosage form in a manner that allows for ready manipulation by the formulator and by the consumer. This generally means that a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 2 mg and 10 mg. Generally, the amount of drug in the composition will vary from about 0.05%w to about 99.0%w. Most preferably the composition will be about 0.2% to about 97.0%w drug.
  • the amount of the pharmaceutically acceptable carrier is that amount needed to provide the necessary stability, dispersibility, consistency and bulking characteristics to ensure a uniform pulmonary delivery of the composition to a subject in need thereof. Numerically the amount may be from about 0.05%w to about 99.95%w, depending on the activity of the drug being employed. Preferably about 5%w to about 95%w will be used.
  • the carrier may be one or a combination of two or more pharmaceutical excipients, but will generally be substantially free of any "penetration enhancers.”
  • Penetration enhancers are surface active compounds which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations .
  • Exemplary penetration enhancers include bile salts, e.g. , taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible detergents, e.g., Tweens, aureth-9, and the like.
  • penetration enhancers in formulations for the lungs, however, is generally undesirable because the epithelial blood barrier in the lung can be adversely affected by such surface active compounds .
  • the dry powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.
  • HSA human serum albumin
  • bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like.
  • These carriers may be in a crystalline or amorphous form or may be a mixture of the two. It has been found that HSA is particularly valuable as a carrier in that it provides improved dispersibility.
  • Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof.
  • Suitable carbohydrates include onosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl-jS-cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like.
  • a preferred group of carbohydrates includes lactose, trehalose, raffinose maltodextrins, and mannitol.
  • Suitable polypeptides include aspartame.
  • Amino acids include alanine and glycine, with glycine being preferred.
  • Additives which are minor components of the composition of this invention, may be included for conformational stability during spray drying and for improving dispersibility of the powder.
  • additives include hydrophobic amino acids such as tryptophan, tyrosine, leucine, phenylalanine, and the like.
  • Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
  • Another aspect of this invention is a unit dosage form for pulmonary delivery of dispersible dry powder pharmaceutical-based compositions, which dosage form comprises a unit dosage receptacle containing a pharmaceutical-based dry powder composition, which composition comprises a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
  • the composition of this invention (as discussed hereinbefore) is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with drug for a unit dosage treatment.
  • the dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the interferon-based dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment.
  • Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition.
  • a stream of gas e.g., air
  • Such containers are exemplified by those shown in U.S. Patents 4,227,522 issued October 14, 1980; 4,192,309 issued March 1 1, 1980; and 4,105,027 issued August 8, 1978.
  • Suitable containers also include those used in conjunction with Glaxo' s Ventolin Rotohaler brand powder inhaler or Fison's Spinhaler brand powder inhaler.
  • Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate.
  • the pharmaceutical-based powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate.
  • a container for use with a powder inhalation device is described in U.S. Patent 4,778,054 and is used with Glaxo's Diskhaler ® (U.S. Patents 4,627,432; 4,811,731; and 5,035,237). All of these references are incorporated herein by reference.
  • Another aspect of this invention is a method of treating a condition responsive to treatment by a pharmaceutical of interest, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of a dispersible pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier.
  • physiologically effective amount needed to treat a particular condition or disease state will depend on the individual, the condition, length of treatment, the regularity of treatment, the type of drug, and other factors, but can be determined by one of ordinary skill in the medicinal arts.
  • the effective absorption by a host of dry powder composition according to the present invention results from a rapid dissolution in the ultra-thin ( ⁇ 0.1 (m) fluid layer of the alveolar lining of the lung.
  • the particles of the present invention thus have a mean size which is from 10 to 50 times larger than the lung fluid layer, making it unexpected that the particles are dissolved and the interferon systemically absorbed in a rapid manner for either local lung or systemic treatment.
  • the aerosolized pharmaceutical-based dry powders of this invention are particularly useful in place of parenteral delivery.
  • the methods and compositions of the present invention will be particularly valuable in chronic treatment protocols where a patient can self-medicate.
  • the patient can achieve a desired dosage by inhaling an appropriate amount of drug, as just described.
  • the efficiency of systemic delivery via the method as just described will typically be in the range from about 15% to 50%.
  • Still another aspect of this invention is a device and method for aerosolizing a pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier, which method comprises dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by a patient.
  • Still another aspect of this invention is a method for preparing a dispersible pharmaceutical-based dry powder composition of this invention that comprises spray drying an aqueous mixture of the drug and a pharmaceutically acceptable carrier under conditions to provide a respirable dry powder composition.
  • Spray drying is a process in which a homogeneous aqueous mixture of drug and the carrier is introduced via a nozzle (e.g., a two fluid nozzle), spinning disc or an equivalent device into a hot gas stream to atomize the solution to form fine droplets.
  • a nozzle e.g., a two fluid nozzle
  • the aqueous mixture may be a solution, suspension, slurry, or the like, but needs to be homogeneous to ensure uniform distribution of the components in the mixture and ultimately the powdered composition.
  • the aqueous mixture is a solution.
  • the solvent generally water, rapidly evaporates from the droplets producing a fine dry powder having particles 1 to 5 ⁇ m in diameter.
  • the drug is not degraded when it is exposed to the hot drying gas, and the interferon powders can be prepared having sufficient purity for pharmaceutical use.
  • An acceptable purity is defined as less than 5% degradation products and contaminates, preferably less than 3% and most preferably less than 1%.
  • the spray drying is done under conditions that result in substantially amorphous powder of homogeneous constitution having a particle size that is respirable, a low moisture content and flow characteristics that allow for ready aerosolization.
  • the particle size of the resulting powder is such that more than about 98% of the mass is in particles having a diameter of about 10 ⁇ m or less with about 90% of the mass being in particles having a diameter less than 5 ⁇ m.
  • about 95% of the mass will have particles with a diameter of less than 10 ⁇ m with about 80% of the mass of the particles having a diameter of less than 5 ⁇ m.
  • the solutions may then be sprayed dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro, Yamato Chemical Co., Okawara Kakoki Co., and the like, resulting in a substantially amorphous particulate product.
  • Such spraying methods as rotary atomization, pressure atomization and two-fluid atomization can be used.
  • the devices used in these processes include “Parubisu [phonetic rendering] Mini-Spray GA-32” and “Parubisu Spray Drier DL-41", manufactured by Yamato Chemical Co., or "Spray Drier CL-8,” “Spray Drier L-8,” “Spray Drier FL-12,” “Spray Drier F -16” or “Spray Drier FL-20,” manufactured by Okawara Kakoki Co., can be used for the method of spraying using rotary-disk atomizer.
  • nozzle types "IA,” “1,” “2A, “ “2,” “3” and the like, manufactured by Yamato Chemical Co. can be used for the above-mentioned spray-drier, manufactured by the same company.
  • disks type "MC-50,” “MC-65” or “MC-85,” manufactured by Okawara Kakoki Co. can be used as rotary disks of the spray-drier atomizer, manufactured by the same company.
  • the temperature of the inlet of the gas used to dry the sprayed materials such that it does not cause heat deactivation of the sprayed material.
  • the range of temperatures may vary between about 50°C to about 200°C, preferably between about 50°C and 100°C.
  • the temperature of the outlet gas used to dry the sprayed material may vary between about 0°C and about 150°, preferably between 0°C and 90°C, and even more preferably between 0°C and 60°C.
  • the dispersible pharmaceutical-based dry powders of the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration.
  • Such carriers may serve simply as bulking agents when it is desired to reduce the interferon concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the interferon compositions and to improve the dispersibility of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the interferon and to improve handling characteristics of the interferon such as flowability and consistency to facilitate manufacturing and powder filling.
  • Such carrier materials may be combined with the drug prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In that way, the carrier particles will be formed simultaneously with the drug particles to produce a homogeneous powder.
  • the carriers may be separately prepared in a dry powder form and combined with the dry powder drug by blending.
  • the powder carriers will usually be crystalline (to avoid water absorption) , but might in some cases be amorphous or mixtures of crystalline and amorphous.
  • the size of the carrier particles may be selected to improve the flowability of the drug powder, typically being in the range from 25 ⁇ m to 100 ⁇ m.
  • a preferred carrier material is crystalline lactose having a size in the above-stated range.
  • dry powder compositions may be prepared by other processes such as lyophilization and jet milling as disclosed in WO 91/16038.
  • EPO Erthropoetin
  • G-CSF Granulocyte Colony Stimulating Neutropenia Factor
  • GM-CSF Granulocyte Macrophage Colony Bone Marrow Engraftment/Transplant Failure Stimulating Factor
  • FSH Follicle Stimulating Hormone
  • GAF Growth Hormone Releasing Factor
  • M-CSF Meth Factor
  • DNase Deoxyribonuclease
  • ARDS Bactericidal/Permeability Adult Respiratory Distress Syndrome
  • Pentamidine isethiouate Pneumocystis carini pneumonia
  • a dry powder of the 20% insulin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • Outlet temperature 80-81°C Once the aqueous mixture was consumed, the outlet temperature was maintained at ⁇ 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the above 20% insulin dry powder composition contained 66.1% mannitol and 13.9% citrate.
  • the composition was found to contain 1.1 to 2.0% moisture as measured by a columbic Karl Fischer method using a Mitsubishi CA-06 Moisture Meter.
  • the particle size distribution of the composition was measured by liquid centrifugal sedimentation in a Horiba CAPA-700 Particle Size Analyzer following dispersion of the powder on Sedisperse A-11 (Micrometrics, Norcross, GA) and was determined to be 1.3 ⁇ m to 1.5 ⁇ m MMD.
  • the delivered dose of the insulin powder composition was measured by collecting the aerosol powder produced by a dry powder dispersion device, similar to devices described in co-pending U.S. Application Serial Numbers 07/910,048; 08/313,707; 08/309,691 and PCT/US92/05621, the disclosures of which are hereby incorporated by reference, on a filter placed over the device mouthpiece.
  • the delivered dose of the insulin powder composition was determined to be 563 ⁇ 16 ⁇ g or 60 to 64% of the total powder (5.0 mg) loaded into the device.
  • the aerosol particle size distribution measured using a cascade impactor (California Measurements IMPAQ-6) , was determined to be 2.0 ⁇ m MMAD, with 86% to 90% of the particles ⁇ 5.0 ⁇ m in diameter.
  • the insulin content of the powder measured by reverse phase HPLC (rpHPLC) was determined to be 197 ⁇ g/mg powder, accounting for 99% of the expected insulin. No degradation peaks were detected in the chromatogram.
  • PTH parathyroid hormone
  • a dry powder of the 5.0% PTH (1-34) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • Outlet temperature 73-74°C Once the aqueous mixture was consumed, the outlet temperature was maintained at ⁇ 80°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • PTH (1-34) dry powder composition contained 81.0% mannitol and 13.9% citrate.
  • the formulation contained 0.5% moisture.
  • the particle size distribution of the composition was determined to be 2.4 ⁇ m and 2.7 ⁇ m MMD in separate measurements.
  • the delivered dose of the PTH (1-34) powder was determined to be 161 ⁇ g or 64.5% and 175 ⁇ g or 69.2% in separate measurements.
  • the PTH (1-34) content of the powder, measured by rpHPLC was determined to be 48.5 ⁇ g/mg powder, accounting for 97% of the expected value. No degradation peaks were detected in the chromatogram.
  • EXAMPLE III 0.7% INTERLEUKIN-1 RECEPTOR FORMULATION FOR PULMONARY DELIVERY
  • IL-1 receptor Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, WA. A 0.7% IL-1 receptor formulation was achieved by combining 0.053 mg IL-1 receptor per 1.0 mL deionized water with 7.07 mg/mL raffinose (Pfanstiehl, Waukegan, IL) and 0.373 mg/mL Tris buffer at pH 7.18.
  • a dry powder of the 0.7% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • the outlet temperature was maintained at 90°C for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • the above 0.7% IL-1 receptor dry powder composition contained 94.3% raffinose and 5.0% Tris.
  • the formulation contained 1.84 ⁇ 0.25% moisture.
  • the particle size distribution of the composition was determined to be 1.95 ⁇ m MMD with 100% of the particles ⁇ 5.0 ⁇ m.
  • the delivered dose of the IL-1 receptor powder was determined to be 22.3 ⁇ 2.0 ⁇ g or 53.4 ⁇ 4.7%.
  • the aerosol particle size distribution was determined to be 3.2 ⁇ m MMAD, with 77% of the particles ⁇ 5.0 ⁇ m in diameter.
  • the IL-1 receptor content of the powder as measured by rpHPLC was determined to be 8.4 ⁇ g/mg, accounting for 120% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
  • IL-1 receptor Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, WA. A 5.0% IL-1 receptor formulation was achieved by combining 0.375 mg IL-1 receptor per 1.0 mL deionized water with 6.77 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.35.
  • a dry powder of the 5.0% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
  • the outlet temperature was maintained at 90°C for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the particle size distribution of the composition was determined to be 2.74 ⁇ m MMD with 97% of the particles ⁇ 5.0 ⁇ m.
  • the delivered dose of the IL-1 receptor powder was determined to be 123.4 ⁇ 24.5 ⁇ g or 49.3 ⁇ 9.8%.
  • the aerosol particle size distribution was determined to be 4.1 ⁇ m MMAD, with 64% of the particles ⁇ 5.0 ⁇ m in diameter.
  • the IL-1 receptor content of the powder as measured by rpHPLC was determined to be 52.7 ⁇ 1.8 ⁇ g/mg, accounting for 105% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
  • a dry powder of the 26.7% human calcitonin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • Example II The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • the above 26.7% human calcitonin dry powder composition contained 60% mannitol and 13.3% citrate.
  • the formulation contained 0.71% moisture.
  • the particle size distribution of the composition was determined to be 1.33 ⁇ 0.63 ⁇ m MMD.
  • the delivered dose of the human calcitonin powder was determined to be 76.8 ⁇ 6.7%.
  • the human calcitonin content of the powder as measured by rpHPLC was determined to be 272.0 ⁇ g/mg, accounting for 102 ⁇ 1.7% of the expected human calcitonin. No degradation peaks were detected in the chromatogram.
  • A1A Bulk alpha-1 antitrypsin, A1A, was obtained from Armour Pharmaceutical Company, Kankakee, IL. A 90% A1A formulation was achieved by combining 4.89 mg A1A per 1.0 mL deionized water with 0.54 mg/mL citrate buffer at pH 6.0.
  • a dry powder of the 90% A1A formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 4°C
  • the outlet temperature was maintained at 69°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the above 90% A1A dry powder composition contained 10.0% citrate.
  • the formulation contained 4.79% moisture.
  • the particle size distribution of the composition was determined to be 1.71 ⁇ 0.87 ⁇ m MMD.
  • the delivered dose of the 90% A1A powder was determined to be 67.0 ⁇ 5.0%.
  • the aerosol particle size distribution was determined to be 1.0 ⁇ m MMAD, with 90% of the particles ⁇ 5.0 ⁇ m in diameter.
  • the A1A content of the powder as measured by rpHPLC was determined to be 80% of the expected value. No degradation peaks were detected in the chromatogram. The activity after spray drying was determined to be 74 + 1%
  • IFN-/3 Bulk beta interferon, IFN-/3, was obtained from Toray Industries, Inc., Tokyo, Japan. A 0.3% IFN-? formulation was achieved by combining 0.025 mg IFN-3 per 1.0 mL deionized water with 5.54 mg/mL human serum albumin (HSA), 2.3 mg/mL citrate buffer and 0.345 mg/mL of NaCl at pH 4.5. B. Spray Drying.
  • a dry powder of the 0.3% IFN-/3 formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
  • the above 0.3% IFN-0 dry powder composition contained 66.0% HSA, 27.4% citrate, 4.1% NaCl.
  • the formulation contained 4.22% moisture.
  • the particle size distribution of the composition was determined to be 1.62 ⁇ m MMD with 94.8% of the particles ⁇ 5 ⁇ m.
  • the delivered dose of the 0.3% IFN-S powder was determined to be 9.9 ⁇ g/mg or 66.0 ⁇ 4.0%.
  • the aerosol particle size distribution was determined to be 2.0 ⁇ m MMAD, with 85% of the particles ⁇ 5.0 ⁇ m in diameter.
  • the IFN-3 activity of the powder as measured by
  • IFN-/3 enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109 ⁇ 8% of the expected activity.
  • IFN-/3 formulation was achieved by combining 0.025 mg IFN- / 3 per 1.0 mL deionized water with 4.7 mg/mL raffinose, 1.0 mg/mL human serum albumin (HSA), 2.3 mg/mL citrate buffer and 0.3 mg/mL of NaCl at pH 4.5.
  • HSA human serum albumin
  • a dry powder of the 0.3% IFN-/5 formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
  • the outlet temperature was maintained at 97°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the above 0.3% IFN-3 dry powder composition contained 56.4% raffinose, 11.9% HSA, 27.4% citrate, 3.5% NaCl.
  • the formulation contained 0.69% moisture.
  • the particle size distribution of the composition was determined to be 2.06 ⁇ m MMD with 88.9% of the particles ⁇ 5 ⁇ m.
  • the delivered dose of the 0.3% IFN-3 powder was determined to be 10.2 ⁇ g/mg or 68.0 ⁇ 2.0%.
  • the aerosol particle size distribution was determined to be 2.5 ⁇ m MMAD, with 84% of the particles ⁇ 5.0 ⁇ m in diameter.
  • IFN-jS activity of the powder as measured by IFN-jS enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109 ⁇ 8% of the expected activity.
  • IFN-jS enzyme immunoassay Toray-Fuji Bionics
  • heparin sodium salt (Av. Mol. Wt. : Approx. 6000) from porcine intestinal mucosa, heparin (LMW), was obtained from Sigma Chemical, St. Louis, MO..
  • a 93% heparin (LMW) formulation was achieved by combining 6.9 mg heparin (LMW) per 1.0 mL deionized water with 0.5 mg/mL HSA at pH 6.9.
  • a dry powder of the 93% heparin (LMW) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • the outlet temperature was maintained at 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the above 93% heparin (LMW) dry powder composition contained 7.0% HSA.
  • the delivered dose of the 93% heparin (LMW) powder was determined to be 60.0 ⁇ 1.0%.
  • the aerosol particle size distribution was determined to be 3.5 ⁇ m MMAD, with 70% of the particles ⁇ 5.0 ⁇ m in diameter.
  • heparin sodium salt from porcine intestinal mucosa was obtained from Sigma Chemical, St. Louis, MO.
  • a 97% heparin formulation was achieved by combining 7.0 mg heparin per 1.0 mL deionized water with 0.25 mg/mL HSA at pH 6.55.
  • a dry powder of the 97% heparin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
  • the outlet temperature was maintained at 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • the above 97% heparin dry powder composition contained 3.0% HSA.
  • the formulation contained 5.11% moisture.
  • the particle size distribution of the composition was determined to be 2.0 to 2.5 ⁇ m MMD.
  • the delivered dose of the 97% heparin powder was determined to be 79.0 ⁇ 6.0%.
  • the aerosol particle size distribution was determined to be 3.2 ⁇ m MMAD, with 70% of the particles ⁇ 5.0 ⁇ m in diameter.
  • a 0.71% DNA:Lipid vector formulation was achieved by combining 0.005:0.03 mg DNA:Lipid vector per 1.0 mL deionized water with 5.3 mg/mL glycine (J.T. Baker) 0.3 mg/mL HSA at pH 6.4.
  • a dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C Inlet temperature 120°C
  • the outlet temperature was maintained at 65°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • DNA:Lipid vector dry powder composition contained 93.97% glycine, and 5.32% HSA.
  • the particle size distribution of the composition was determined to be 2.0 ⁇ m MMD.
  • the delivered dose of the 97% heparin (HMW) powder was determined to be 64.0 ⁇ 1.0%.
  • the aerosol particle size distribution was determined to be 2.4 ⁇ m MMAD, with 75% of the particles ⁇ 5. 0 ⁇ m in diameter.
  • a dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
  • the following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • the above DNA:adenovirous vector dry powder composition contained 58% glycine, and 24% HSA and 18% phosphate buffer.
  • the particle size distribution of the composition was determined to be 2.3 ⁇ m MMD.
  • the delivered dose of the 97% heparin (HMW) powder was determined to be 51.0 ⁇ 1.0%.
  • the aerosol particle size distribution was determined to be 1.8 ⁇ m MMAD, with 80% of the particles ⁇ 5.0 ⁇ m in diameter. Activity after spray drying was determined to be 76% of the expected value.

Abstract

According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry power pharmaceutical-based composition is one having a moisture content of less than about 10 % by weight (%w) water, usually below about 5 %w and preferably less than about 3 %w; a particle size of about 1.0-5.0 νm mass median diameter (MMD), usually1.0-4.0 νm MMD, and preferably 1.0-3.0 νm MMD; a delivered dose of about >30 %, usually >40 %, preferably >50 %, and most preferred >60 %; and an aerosol particle size distribution of about 1.0-5.0 νm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 νm MMAD, and preferably 1.5-4.0 νm MMAD. Such composistions are of pharmaceutical grade purity.

Description

PULMONARY DELIVERY OF AEROSOLIZED MEDICAMENTS
BACKGROUND OF THE INVENTION
1. Field of the Invention.
The present invention relates generally to methods and compositions for the dry powder formulation of pharmaceuticals, including macromolecules, for pulmonary delivery.
Over the years, certain drugs have been sold in compositions suitable for forming a drug dispersion for oral inhalation (pulmonary delivery) to treat various conditions in humans. Such pulmonary drug delivery compositions are designed to be delivered by inhalation by the patient of a drug dispersion so that the active drug within the dispersion can reach the lung. It has been found that certain drugs delivered to the lung are readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery is particularly promising for the delivery of macromolecules (proteins, polypeptides and nucleic acids) which are difficult to deliver by other routes of administration. Such pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
Pulmonary drug delivery can itself be achieved by different approaches, including liquid nebulizers, aerosol-based metered dose inhalers (MDI's), and dry powder dispersion devices. Aerosol-based MDI's are losing favor because they rely on the use of chlorofluorocarbons (CFC's), which are being banned because of their adverse effect on the ozone layer. Dry powder dispersion devices, which do not rely on CFC aerosol technology, are promising for delivering drugs that may be readily formulated as dry powders. Many otherwise labile macromolecules may be stably stored as lyophilized or spray-dried powders by themselves or in combination with suitable powder carriers. The ability to deliver pharmaceutical compositions as dry powders, however, is problematic in certain respects. The dosage of many pharmaceutical compositions is often critical so it is necessary that any dry powder delivery system be able to accurately, precisely, and reliably deliver the intended amount of drug. Moreover, many pharmaceutical compositions are quite expensive. Thus, the ability to efficiently deliver the dry powders with a minimal loss of drug is critical. It is also essential that the powder be readily dispersible prior to inhalation by the patient in order to assure adequate distribution and systemic absorption.
A particularly promising approach for the pulmonary delivery of dry powder drugs utilizes a hand-held device with a hand pump for providing a source of pressurized gas. The pressurized gas is abruptly released through a powder dispersion device, such as a venturi nozzle, and the dispersed powder made available for patient inhalation. While advantageous in many respects, such hand-held devices are problematic in a number of other respects. The particles being delivered are less than 10 μm in size, usually in the range from lμm to 5μm, making powder handling and dispersion more difficult than with larger particles. The problems are exacerbated by the relatively small volumes of pressurized gas, which are available using hand-actuated pumps. In particular, venturi dispersion devices are unsuitable for difficult-to-disperse powders when only small volumes of pressurized gas are available. Another requirement for hand-held and other powder delivery devices is efficiency. It is important that the concentration of drug in the bolus of gas be relatively high to reduce the number of breaths required to achieve a total dosage. The ability to achieve both adequate dispersion and small dispersed volumes is a significant technical challenge that requires in part that each unit dosage of the powdered composition be readily and reliably dispersible.
SUMMARY OF THE INVENTION According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD. Such compositions are of pharmaceutical grade purity.
DESCRIPTION OF SPECIFIC EMBODIMENTS
The present invention is based at least in part on the dispersibility characteristics of the pharmaceutical-based dry powder compositions produced according to the present invention. The dispersibility characteristics of the subject pharmaceutical-based compositions means that they are more suitable for use in pulmonary delivery devices than compositions prepared by other methods. The compositions of the invention are readily aerosolized and rapidly absorbed through the lungs of a host when delivered by a dry powder inhaler.
DEFINITIONS
In interpreting the claims to the various aspects of this invention, there are several important definitions that should be considered.
The term "dispersibility" or "dispersible" means a dry powder having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD) , usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD) , usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD.
The term "powder" means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli. Thus, the powder is said to be "respirable. " Preferably the average particle size is less than about 10 microns (μm) in diameter with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 μm and most preferably less than about 5.0 μm. Usually the particle size distribution is between about 0.1 μm and about 5 μm in diameter, particularly about 0.3 μm to about 5 μm. The term "dry" means that the composition has a moisture content such that the particles are readily dispersible in an inhalation device to form an aerosol. This moisture content is generally below about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w.
The term "therapeutically effective amount" is the amount present in the composition that is needed to provide the desired level of drug in the subject to be treated to give the anticipated physiological response. This amount is determined for each drug on a case-by-case basis. Guidelines are given hereafter.
The term "physiologically effective amount" is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each drug and its ultimate approved dosage level. Guidelines are given hereafter. The term "pharmaceutically acceptable carrier" means that the carrier can be taken into the lungs with no significant adverse toxicological effects on the lungs.
COMPOSITIONS OF THE INVENTION
One aspect of this invention is a dispersible pharmaceutical-based dry powder composition for pulmonary delivery, the composition comprising a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
In general, the compositions of this invention have a suitable for pulmonary delivery because of their dispersibility characteristics. Such compositions were not previously known in the art. In the dry state, the pharmaceutical may be in crystalline or amorphous form. Some examples of pharmaceutical compositions suitable for formulation into dispersible dry powders are listed in Table 1. These include macromolecule and non-macromolecule-based pharmaceuticals, usually macromolecules, with insulin, interleukin-1 receptor, parathyroid hormone (PTH-34) , alpha-1 antitrypsin, calcitonin, low molecular weight heparin, heparin, interferon, and nucleic acids being preferred. A therapeutically effective amount of active pharmaceutical will vary in the composition depending on the biological activity of the drug employed and the amount needed in a unit dosage form. Because the subject compounds are dispersible, it is highly preferred that they be manufactured in a unit dosage form in a manner that allows for ready manipulation by the formulator and by the consumer. This generally means that a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 2 mg and 10 mg. Generally, the amount of drug in the composition will vary from about 0.05%w to about 99.0%w. Most preferably the composition will be about 0.2% to about 97.0%w drug.
The amount of the pharmaceutically acceptable carrier is that amount needed to provide the necessary stability, dispersibility, consistency and bulking characteristics to ensure a uniform pulmonary delivery of the composition to a subject in need thereof. Numerically the amount may be from about 0.05%w to about 99.95%w, depending on the activity of the drug being employed. Preferably about 5%w to about 95%w will be used.
The carrier may be one or a combination of two or more pharmaceutical excipients, but will generally be substantially free of any "penetration enhancers." Penetration enhancers are surface active compounds which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations . Exemplary penetration enhancers include bile salts, e.g. , taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible detergents, e.g., Tweens, aureth-9, and the like. The use of penetration enhancers in formulations for the lungs, however, is generally undesirable because the epithelial blood barrier in the lung can be adversely affected by such surface active compounds . The dry powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.
The types of pharmaceutical excipients that are useful as carriers in this invention include stabilizers such as human serum albumin (HSA) . bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two. It has been found that HSA is particularly valuable as a carrier in that it provides improved dispersibility.
Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof. Suitable carbohydrates include onosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl-jS-cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like. A preferred group of carbohydrates includes lactose, trehalose, raffinose maltodextrins, and mannitol. Suitable polypeptides include aspartame. Amino acids include alanine and glycine, with glycine being preferred.
Additives, which are minor components of the composition of this invention, may be included for conformational stability during spray drying and for improving dispersibility of the powder. These additives include hydrophobic amino acids such as tryptophan, tyrosine, leucine, phenylalanine, and the like.
Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
The unit dosage form, method of treatment, and process of preparation of this invention are described hereafter.
Unit Dosage Form.
Another aspect of this invention is a unit dosage form for pulmonary delivery of dispersible dry powder pharmaceutical-based compositions, which dosage form comprises a unit dosage receptacle containing a pharmaceutical-based dry powder composition, which composition comprises a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
In this aspect of the invention, the composition of this invention (as discussed hereinbefore) is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with drug for a unit dosage treatment. The dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the interferon-based dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment. Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition. Such containers are exemplified by those shown in U.S. Patents 4,227,522 issued October 14, 1980; 4,192,309 issued March 11, 1980; and 4,105,027 issued August 8, 1978. Suitable containers also include those used in conjunction with Glaxo' s Ventolin Rotohaler brand powder inhaler or Fison's Spinhaler brand powder inhaler. Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate. The pharmaceutical-based powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate. Such a container for use with a powder inhalation device is described in U.S. Patent 4,778,054 and is used with Glaxo's Diskhaler® (U.S. Patents 4,627,432; 4,811,731; and 5,035,237). All of these references are incorporated herein by reference.
Method of Treating a Disease State.
Another aspect of this invention is a method of treating a condition responsive to treatment by a pharmaceutical of interest, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of a dispersible pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier.
Conditions that may be treated by the compositions of this are described in Table 1.
The physiologically effective amount needed to treat a particular condition or disease state will depend on the individual, the condition, length of treatment, the regularity of treatment, the type of drug, and other factors, but can be determined by one of ordinary skill in the medicinal arts.
It is presently believed that the effective absorption by a host of dry powder composition according to the present invention results from a rapid dissolution in the ultra-thin (<0.1 (m) fluid layer of the alveolar lining of the lung. The particles of the present invention thus have a mean size which is from 10 to 50 times larger than the lung fluid layer, making it unexpected that the particles are dissolved and the interferon systemically absorbed in a rapid manner for either local lung or systemic treatment. An understanding of the precise mechanism, however, is not necessary for practicing the present invention as described herein.
The aerosolized pharmaceutical-based dry powders of this invention are particularly useful in place of parenteral delivery. Thus, the methods and compositions of the present invention will be particularly valuable in chronic treatment protocols where a patient can self-medicate. The patient can achieve a desired dosage by inhaling an appropriate amount of drug, as just described. The efficiency of systemic delivery via the method as just described will typically be in the range from about 15% to 50%.
Method for Aerosolizing the Powder. Still another aspect of this invention is a device and method for aerosolizing a pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier, which method comprises dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by a patient.
A further detailed description of this method is found in pending U.S. Patent Application Serial Nos. : 07/910,048 and 08/207,472, both of which are incorporated herein by reference.
Preparing the Compositions.
Still another aspect of this invention is a method for preparing a dispersible pharmaceutical-based dry powder composition of this invention that comprises spray drying an aqueous mixture of the drug and a pharmaceutically acceptable carrier under conditions to provide a respirable dry powder composition.
Spray drying is a process in which a homogeneous aqueous mixture of drug and the carrier is introduced via a nozzle (e.g., a two fluid nozzle), spinning disc or an equivalent device into a hot gas stream to atomize the solution to form fine droplets. The aqueous mixture may be a solution, suspension, slurry, or the like, but needs to be homogeneous to ensure uniform distribution of the components in the mixture and ultimately the powdered composition.
Preferably the aqueous mixture is a solution. The solvent, generally water, rapidly evaporates from the droplets producing a fine dry powder having particles 1 to 5 μm in diameter. Surprisingly, the drug is not degraded when it is exposed to the hot drying gas, and the interferon powders can be prepared having sufficient purity for pharmaceutical use. An acceptable purity is defined as less than 5% degradation products and contaminates, preferably less than 3% and most preferably less than 1%. The spray drying is done under conditions that result in substantially amorphous powder of homogeneous constitution having a particle size that is respirable, a low moisture content and flow characteristics that allow for ready aerosolization. Preferably the particle size of the resulting powder is such that more than about 98% of the mass is in particles having a diameter of about 10 μm or less with about 90% of the mass being in particles having a diameter less than 5 μm. Alternatively, about 95% of the mass will have particles with a diameter of less than 10 μm with about 80% of the mass of the particles having a diameter of less than 5 μm.
The solutions may then be sprayed dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro, Yamato Chemical Co., Okawara Kakoki Co., and the like, resulting in a substantially amorphous particulate product.
For the spraying process, such spraying methods as rotary atomization, pressure atomization and two-fluid atomization can be used. Examples of the devices used in these processes include "Parubisu [phonetic rendering] Mini-Spray GA-32" and "Parubisu Spray Drier DL-41", manufactured by Yamato Chemical Co., or "Spray Drier CL-8," "Spray Drier L-8," "Spray Drier FL-12," "Spray Drier F -16" or "Spray Drier FL-20," manufactured by Okawara Kakoki Co., can be used for the method of spraying using rotary-disk atomizer.
While no special restrictions are placed on the nozzle of the atomizer used in the process of spraying, it is recommended to use a nozzle which can produce a spray-dry composition with a grain diameter suitable for nasal, pharyngeal or pulmonary administration. For example, nozzle types "IA," "1," "2A, " "2," "3" and the like, manufactured by Yamato Chemical Co., can be used for the above-mentioned spray-drier, manufactured by the same company. In addition, disks type "MC-50," "MC-65" or "MC-85," manufactured by Okawara Kakoki Co., can be used as rotary disks of the spray-drier atomizer, manufactured by the same company.
While no particular restrictions are placed on the gas used to dry the sprayed material, it is recommended to use air, nitrogen gas or an inert gas. The temperature of the inlet of the gas used to dry the sprayed materials such that it does not cause heat deactivation of the sprayed material. The range of temperatures may vary between about 50°C to about 200°C, preferably between about 50°C and 100°C. The temperature of the outlet gas used to dry the sprayed material, may vary between about 0°C and about 150°, preferably between 0°C and 90°C, and even more preferably between 0°C and 60°C. The fact that inlet and outlet temperatures above about 55°C can be used is surprising in view of the fact that most macromolecule-based drugs deactivate at that temperature, with nearly complete deactivation occurring at about 70°C.
The dispersible pharmaceutical-based dry powders of the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration. Such carriers may serve simply as bulking agents when it is desired to reduce the interferon concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the interferon compositions and to improve the dispersibility of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the interferon and to improve handling characteristics of the interferon such as flowability and consistency to facilitate manufacturing and powder filling.
Such carrier materials may be combined with the drug prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In that way, the carrier particles will be formed simultaneously with the drug particles to produce a homogeneous powder. Alternatively, the carriers may be separately prepared in a dry powder form and combined with the dry powder drug by blending. The powder carriers will usually be crystalline (to avoid water absorption) , but might in some cases be amorphous or mixtures of crystalline and amorphous. The size of the carrier particles may be selected to improve the flowability of the drug powder, typically being in the range from 25 μm to 100 μm. A preferred carrier material is crystalline lactose having a size in the above-stated range.
Alternatively, dry powder compositions may be prepared by other processes such as lyophilization and jet milling as disclosed in WO 91/16038.
TABLE 1
SELECTED MACROMOLECULE DRUGS FOR SYSTEMIC APPLICATIONS
DRUG INDICATIONS
Calcitoni Osteoporosis Prophylaxis Paget's Disease Hypercalcemia
Erthropoetin (EPO) Anemia
Factor IX Hemophilia B
Granulocyte Colony Stimulating Neutropenia Factor (G-CSF)
Granulocyte Macrophage Colony Bone Marrow Engraftment/Transplant Failure Stimulating Factor (GM-CSF)
Growth Hormone Short Stature Renal Failure
Heparin Blood Clotting
Heparin (Low Molecular Weight) Blood Clotting
Insulin Type I and Type II Diabetes
Interferon Alpha Hepatitis B and C Hairy Cell Leukemia Kaposi's Sarcoma
Interferon Beta Multiple Sclerosis
Interferon Gamma Chronic Granulomatous Disease
Interleukin-2 Renal Cancer
Luteinizing Hormone Releasing Prostate Cancer Hormone (LHRH) Endometriosis
Somatostatin Analog Gastrointestinal Cancers
Vasopressin Analog Diabetes Insipidus Bed Wetting
Follicle Stimulating Hormone (FSH) Fertility
Amylin Type I Diabetes
Ciliary Neurotrophic Factor Lou Gehrig's Disease
Growth Hormone Releasing Factor (GRF) Short Stature
Insulin-Like Growth Factor Osteoporosis Nutritional Support
Insulinotropin Type II Diabetes
Interferon Beta Hepatitis B and C
Interferon Gamma Rheumatoid Arthritis
Interleukin-1 Receptor Antagonist Rheumatoid Arthritis
Interleukin-3 Adjuvant to Chemotherapy
Interleukin-4 Immunodeficiency Disease
Interleukin-6 Thrombocytopenia TABLE 1 - Continued
SELECTED MACROMOLECULE DRUGS FOR SYSTEMIC APPLICATIONS
DRUG INDICATIONS
Macrophage Colony Stimulating Fungal Disease
Factor (M-CSF) Cancer
Hypercholesterolemia
Nerve Growth Factor Peripheral Neuropathies
Parathyroid Hormone Osteoporosis
Somatostatin Analog Refractory Diarrheas
ThymosLn Alpha 1 Hepatitis B and C
Ilb/IIIa Inhibitor Unstable Angina
Alpha- 1 Antitrypsin Cystic Fibrosis
Anti-RSV Antibody Respiratory Syncytial Virus
Cystic Fibrosis Transmembrane Cystic Fibrosis
Regulator (CFTR) Gene
Deoxyribonuclease (DNase) Chronic Bronchitis
Heparin Asthma
Bactericidal/Permeability Adult Respiratory Distress Syndrome (ARDS)
Increasing Protein (BPI)
Anti-CMV Antibody Cytomegalovirus
Interleukin-1 Receptor Asthma
SELECTED NON-MACROMOLECULE DRUGS FOR SYSTEMIC AND LOCAL LUNG APPLICATIONS
DRUG INDICATIONS
Pentamidine isethiouate Pneumocystis carini pneumonia
Albuterol sulfate Bronchospasm
Metaproterenol sulfate Bronchial asthma
Beclomethasone diprepionate
Triamcinolone acetamide
Budesonide acetonide
Ipratropium bromide
Flunisolide
Cromolyn sodium
Ergotamine Tartrate Migraines
The following examples are offered by way of illustration and not limitation . EXPERIMENTAL According the subject invention, the following dispersible dry powder formulations were prepared as described. All compositions produced according to the present invention meet the strict specifications for content and purity required of pharmaceutical products.
EXAMPLE I 20.0% INSULIN FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk crystalline human zinc insulin, was obtained from Eli Lilly and Company, Indianapolis, IN. A 20% insulin formulation was achieved by combining 1.5 mg insulin per 1.0 mL deionized water with 4.96 mg/mL USP mannitol and 1.04 mg/mL citrate buffer (sodium citrate dihydrate USP and citric acid monohydrate USP) for a total solids concentration of 7.5 mg/mL at pH 6.7 ± 0.3.
B. Spray Drying.
A dry powder of the 20% insulin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 2-8°C
Inlet temperature 120-122°C
Feed rate 5.3 mL/min
Outlet temperature 80-81°C Once the aqueous mixture was consumed, the outlet temperature was maintained at < 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The above 20% insulin dry powder composition contained 66.1% mannitol and 13.9% citrate. The composition was found to contain 1.1 to 2.0% moisture as measured by a columbic Karl Fischer method using a Mitsubishi CA-06 Moisture Meter.
The particle size distribution of the composition was measured by liquid centrifugal sedimentation in a Horiba CAPA-700 Particle Size Analyzer following dispersion of the powder on Sedisperse A-11 (Micrometrics, Norcross, GA) and was determined to be 1.3 μm to 1.5 μm MMD.
The delivered dose of the insulin powder composition was measured by collecting the aerosol powder produced by a dry powder dispersion device, similar to devices described in co-pending U.S. Application Serial Numbers 07/910,048; 08/313,707; 08/309,691 and PCT/US92/05621, the disclosures of which are hereby incorporated by reference, on a filter placed over the device mouthpiece. The delivered dose of the insulin powder composition was determined to be 563 ± 16 μg or 60 to 64% of the total powder (5.0 mg) loaded into the device.
The aerosol particle size distribution, measured using a cascade impactor (California Measurements IMPAQ-6) , was determined to be 2.0 μm MMAD, with 86% to 90% of the particles < 5.0 μm in diameter.
The insulin content of the powder, measured by reverse phase HPLC (rpHPLC) was determined to be 197 μg/mg powder, accounting for 99% of the expected insulin. No degradation peaks were detected in the chromatogram.
EXAMPLE II 5.0% PARATHYROID HORMONE FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk 34 amino acid active fragment of parathyroid hormone, PTH (1-34) , was obtained from BACHEM CALIFORNIA, Torrance, CA. A 5.0% PTH (1-34) formulation was achieved by combining 0.375 mg PTH (1-34) per 1.0 mL deionized water with 6.06 mg/mL mannitol USP and 1.04 mg/mL citrate buffer (sodium citrate dihydrate USP and citric acid monohydrate USP) for a total solids concentration of 7.48 mg/mL at pH 6.3. B. Spray Dryin .
A dry powder of the 5.0% PTH (1-34) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 2-8°C Inlet temperature 122-124°C
Feed rate 5.2 mL/min
Outlet temperature 73-74°C Once the aqueous mixture was consumed, the outlet temperature was maintained at < 80°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 5.0% PTH (1-34) dry powder composition contained 81.0% mannitol and 13.9% citrate. The formulation contained 0.5% moisture.
The particle size distribution of the composition was determined to be 2.4 μm and 2.7 μm MMD in separate measurements. The delivered dose of the PTH (1-34) powder was determined to be 161 μg or 64.5% and 175 μg or 69.2% in separate measurements.
The PTH (1-34) content of the powder, measured by rpHPLC was determined to be 48.5 μg/mg powder, accounting for 97% of the expected value. No degradation peaks were detected in the chromatogram. EXAMPLE III 0.7% INTERLEUKIN-1 RECEPTOR FORMULATION FOR PULMONARY DELIVERY
A. Formulation. Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, WA. A 0.7% IL-1 receptor formulation was achieved by combining 0.053 mg IL-1 receptor per 1.0 mL deionized water with 7.07 mg/mL raffinose (Pfanstiehl, Waukegan, IL) and 0.373 mg/mL Tris buffer at pH 7.18.
B. Spray Drying.
A dry powder of the 0.7% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 2-8°C
Inlet temperature 135-137°C
Feed rate 4. mL/min Outlet temperature 92-93°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 90°C for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise. The above 0.7% IL-1 receptor dry powder composition contained 94.3% raffinose and 5.0% Tris. The formulation contained 1.84 ± 0.25% moisture.
The particle size distribution of the composition was determined to be 1.95 μm MMD with 100% of the particles < 5.0 μm.
The delivered dose of the IL-1 receptor powder was determined to be 22.3 ± 2.0 μg or 53.4 ± 4.7%. The aerosol particle size distribution, was determined to be 3.2 μm MMAD, with 77% of the particles < 5.0 μm in diameter.
The IL-1 receptor content of the powder as measured by rpHPLC was determined to be 8.4 μg/mg, accounting for 120% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
EXAMPLE IV
5.0% INTERLEUKIN-1 RECEPTOR FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, WA. A 5.0% IL-1 receptor formulation was achieved by combining 0.375 mg IL-1 receptor per 1.0 mL deionized water with 6.77 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.35.
B. Spray Drying.
A dry powder of the 5.0% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
Inlet temperature 138°C
Feed rate 4.9 mL/min
Outlet temperature 91°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 90°C for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization. The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise. The above 5.0% IL-1 receptor dry powder composition contained 90.3% raffinose and 4.7% Tris. The formulation contained 1.75 ± 0.26% moisture.
The particle size distribution of the composition was determined to be 2.74 μm MMD with 97% of the particles < 5.0 μm.
The delivered dose of the IL-1 receptor powder was determined to be 123.4 ± 24.5 μg or 49.3 ± 9.8%.
The aerosol particle size distribution, was determined to be 4.1 μm MMAD, with 64% of the particles < 5.0 μm in diameter.
The IL-1 receptor content of the powder as measured by rpHPLC was determined to be 52.7 ± 1.8 μg/mg, accounting for 105% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
EXAMPLE V 26.7% HUMAN CALCITONIN FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk human calcitonin was obtained from Ciba-Geigy. A 26.7% human calcitonin formulation was achieved by combining 1.9 mg human calcitonin per 1.0 mL deionized water with 4.3 mg/mL mannitol and 0.9 mg/mL citrate buffer at pH 3.85.
B. Spray Drying.
A dry powder of the 26.7% human calcitonin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 4°C
Inlet temperature 119°C
Feed rate 5.5 mL/min
Outlet temperature 78°C Atomizer coolant temperature 0-5°C
Cyclone coolant temperature 25-30°C Once the aqueous mixture was consumed, the outlet temperature was maintained at 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise. The above 26.7% human calcitonin dry powder composition contained 60% mannitol and 13.3% citrate. The formulation contained 0.71% moisture.
The particle size distribution of the composition was determined to be 1.33 ± 0.63 μm MMD. The delivered dose of the human calcitonin powder was determined to be 76.8 ± 6.7%.
The human calcitonin content of the powder as measured by rpHPLC was determined to be 272.0 μg/mg, accounting for 102 ± 1.7% of the expected human calcitonin. No degradation peaks were detected in the chromatogram.
EXAMPLE VI 90% ALPHA-1 ANTITRYPSIN FORMULATION FOR PULMONARY DELIVERY
Formulation.
Bulk alpha-1 antitrypsin, A1A, was obtained from Armour Pharmaceutical Company, Kankakee, IL. A 90% A1A formulation was achieved by combining 4.89 mg A1A per 1.0 mL deionized water with 0.54 mg/mL citrate buffer at pH 6.0.
B. Spray Drying.
A dry powder of the 90% A1A formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 4°C
Inlet temperature 98-101°C
Feed rate 5.0 mL/min Outlet temperature 65°C
Atomizer coolant temperature 2-8°C
Cyclone coolant temperature 30°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 69°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
Characterization. The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 90% A1A dry powder composition contained 10.0% citrate. The formulation contained 4.79% moisture. The particle size distribution of the composition was determined to be 1.71 ± 0.87 μm MMD.
The delivered dose of the 90% A1A powder was determined to be 67.0 ± 5.0%.
The aerosol particle size distribution, was determined to be 1.0 μm MMAD, with 90% of the particles < 5.0 μm in diameter.
The A1A content of the powder as measured by rpHPLC was determined to be 80% of the expected value. No degradation peaks were detected in the chromatogram. The activity after spray drying was determined to be 74 + 1%
EXAMPLE VII 0.3% BETA INTERFERON FORMULATION FOR PULMONARY DELIVERY CONTAINING HUMAN SERUM ALBUMIN
A. Formulation.
Bulk beta interferon, IFN-/3, was obtained from Toray Industries, Inc., Tokyo, Japan. A 0.3% IFN-? formulation was achieved by combining 0.025 mg IFN-3 per 1.0 mL deionized water with 5.54 mg/mL human serum albumin (HSA), 2.3 mg/mL citrate buffer and 0.345 mg/mL of NaCl at pH 4.5. B. Spray Drying.
A dry powder of the 0.3% IFN-/3 formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
Inlet temperature 93°C
Feed rate 2.7 mL/min
Outlet temperature 62°C
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 0.3% IFN-0 dry powder composition contained 66.0% HSA, 27.4% citrate, 4.1% NaCl. The formulation contained 4.22% moisture.
The particle size distribution of the composition was determined to be 1.62 μm MMD with 94.8% of the particles < 5 μm. The delivered dose of the 0.3% IFN-S powder was determined to be 9.9 μg/mg or 66.0 ± 4.0%.
The aerosol particle size distribution, was determined to be 2.0 μm MMAD, with 85% of the particles < 5.0 μm in diameter. The IFN-3 activity of the powder as measured by
IFN-/3 enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109 ± 8% of the expected activity.
EXAMPLE VIII
0.3% BETA INTERFERON FORMULATION FOR PULMONARY DELIVERY
CONTAINING RAFFINOSE
A. Formulation. Bulk beta interferon, IFN-3, was obtained from Toray
Industries, Inc., Tokyo, Japan. A 0.3% IFN-/3 formulation was achieved by combining 0.025 mg IFN-/3 per 1.0 mL deionized water with 4.7 mg/mL raffinose, 1.0 mg/mL human serum albumin (HSA), 2.3 mg/mL citrate buffer and 0.3 mg/mL of NaCl at pH 4.5.
B. Spray Drying. A dry powder of the 0.3% IFN-/5 formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
Inlet temperature 145°C Feed rate 5.0 mL/min
Outlet temperature 87°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 97°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 0.3% IFN-3 dry powder composition contained 56.4% raffinose, 11.9% HSA, 27.4% citrate, 3.5% NaCl. The formulation contained 0.69% moisture.
The particle size distribution of the composition was determined to be 2.06 μm MMD with 88.9% of the particles ■ 5 μm.
The delivered dose of the 0.3% IFN-3 powder was determined to be 10.2 μg/mg or 68.0 ± 2.0%.
The aerosol particle size distribution, was determined to be 2.5 μm MMAD, with 84% of the particles < 5.0 μm in diameter.
The IFN-jS activity of the powder as measured by IFN-jS enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109 ± 8% of the expected activity. EXAMPLE IX 93% LOW MOLECULAR WEIGHT HEPARIN FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk low molecular weight heparin sodium salt (Av. Mol. Wt. : Approx. 6000) from porcine intestinal mucosa, heparin (LMW), was obtained from Sigma Chemical, St. Louis, MO.. A 93% heparin (LMW) formulation was achieved by combining 6.9 mg heparin (LMW) per 1.0 mL deionized water with 0.5 mg/mL HSA at pH 6.9.
B. Spray Drying.
A dry powder of the 93% heparin (LMW) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 2-8°C
Inlet temperature 140°C
Feed rate 3.8 mL/min Outlet temperature 85°C
Atomizer coolant temperature 2-8°C
Cyclone coolant temperature 20°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 93% heparin (LMW) dry powder composition contained 7.0% HSA.
The delivered dose of the 93% heparin (LMW) powder was determined to be 60.0 ± 1.0%.
The aerosol particle size distribution, was determined to be 3.5 μm MMAD, with 70% of the particles < 5.0 μm in diameter. EXAMPLE X 97% UNFRACTIONATED HEPARIN FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk unfractionated heparin sodium salt from porcine intestinal mucosa, heparin, was obtained from Sigma Chemical, St. Louis, MO. A 97% heparin formulation was achieved by combining 7.0 mg heparin per 1.0 mL deionized water with 0.25 mg/mL HSA at pH 6.55.
B. Spray Drying.
A dry powder of the 97% heparin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of aqueous mixture 2-8°C
Inlet temperature 150°C
Feed rate 4.0 mL/min
Outlet temperature 85°C Atomizer coolant temperature 2-8°C
Cyclone coolant temperature 20°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 80°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
The above 97% heparin dry powder composition contained 3.0% HSA. The formulation contained 5.11% moisture.
The particle size distribution of the composition was determined to be 2.0 to 2.5 μm MMD. The delivered dose of the 97% heparin powder was determined to be 79.0 ± 6.0%. O 96/32149
27
The aerosol particle size distribution, was determined to be 3.2 μm MMAD, with 70% of the particles < 5.0 μm in diameter.
EXAMPLE XI LIPID VECTOR GENE FORMULATION FOR PULMONARY DELIVERY
Formulation. Bulk pCMV? DNA:Lipid vector was obtained from
Genzy e Corporation, Cambridge, MA. A 0.71% DNA:Lipid vector formulation was achieved by combining 0.005:0.03 mg DNA:Lipid vector per 1.0 mL deionized water with 5.3 mg/mL glycine (J.T. Baker) 0.3 mg/mL HSA at pH 6.4. B. Spray Drying.
A dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C Inlet temperature 120°C
Feed rate 3.8 mL/min
Outlet temperature 71°C
Atomizer coolant temperature 2-8°C Cyclone coolant temperature 2-8°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 65°C for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise. The above 0.71% DNA:Lipid vector dry powder composition contained 93.97% glycine, and 5.32% HSA.
The particle size distribution of the composition was determined to be 2.0 μm MMD. The delivered dose of the 97% heparin (HMW) powder was determined to be 64.0 ± 1.0%.
The aerosol particle size distribution, was determined to be 2.4 μm MMAD, with 75% of the particles < 5.0 μm in diameter.
Activity after spray drying was determined to be 160% of the expected value.
EXAMPLE XII
ADENOVIRAL VECTOR GENE FORMULATION FOR PULMONARY DELIVERY
A. Formulation.
Bulk pCMV/β DNA:Adenovirous vector was obtained from Genzy e Corporation, Cambridge, MA. A DNA:adenovirous vector formulation was achieved by combining 108 PFU/mL DNA:Lipid vector per 1.0 mL deionized water with 6.1 mg/mL glycine J.T. Baker) 2.5 mg/mL HSA, 1.9 mg/mL phosphate buffer at pH 7.4.
B. Spray Drying.
A dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions: Temperature of aqueous mixture 2-8°C
Inlet temperature 105°C
Feed rate 2.9 mL/min
Outlet temperature 72°C
Atomizer coolant temperature 2-8°C Cyclone coolant temperature 20°C
Once the aqueous mixture was consumed, the outlet temperature was maintained at 70°C for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying. C. Characterization.
The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise. The above DNA:adenovirous vector dry powder composition contained 58% glycine, and 24% HSA and 18% phosphate buffer.
The particle size distribution of the composition was determined to be 2.3 μm MMD. The delivered dose of the 97% heparin (HMW) powder was determined to be 51.0 ± 1.0%.
The aerosol particle size distribution, was determined to be 1.8 μm MMAD, with 80% of the particles < 5.0 μm in diameter. Activity after spray drying was determined to be 76% of the expected value.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A dispersible pharmaceutical-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier, wherein the composition comprises particles and wherein 95% of the mass of the composition comprises particles having a particle size below 10 μm.
2. A dispersible pharmaceutical-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of a macromolecule selected from the group consisting of interleukin 1 receptor, heparin, low molecular weight heparin, and calcitonin, in combination with pharmaceutically acceptable carrier.
3. The composition of claim 1 or 2, wherein the composition is substantially free from penetration enhancers.
4. The composition of claim 2 or 3 , wherein the carrier comprises HSA.
5. The composition of claim 3 or 4, wherein the carrier further comprises a carbohydrate bulking agent.
6. The composition of claim 1 or 2, wherein about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.
7. The composition of claim 1 or 6, wherein about 80% of the mass of the dry powder composition has a particle size of less than 5μm.
8. The composition of claim 1, wherein the pharmaceutical comprises a macromolecule selected from the group consisting of insulin, interleukin 1 receptor, parathyroid hormone alpha-1 antitrypsin, calcitonin, low molecular weight heparin, and nucleic acids.
9. A unit dosage form for pulmonary delivery of a pharmaceutical, which dosage form comprises a unit dosage receptacle containing a dispersible pharmaceutical-based dry powder composition, which composition comprises a therapeutically effective amount of the pharmaceutical in combination with a pharmaceutically acceptable carrier according to any of claims 1-8.
10. A method of treating a disease state responsive to treatment by a pharmaceutical, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of a dispersible pharmaceutical-based dry powder composition according to any of claims 1-8.
11. A method for aerosolizing a pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of the pharmaceutical in combination with a pharmaceutically acceptable carrier, which method comprises: dispersing an amount of a dry powder composition according to any of claims 1-8 in a gas stream to form an aerosol and capturing the aerosol in a chamber suitable for subsequent inhalation by a patient.
12. A method for preparing a spray-dried, pharmaceutical-based dry powder that comprises a therapeutically effective amount of a pharmaceutical and a pharmaceutically acceptable carrier, which method comprises spray drying an aqueous mixture of the pharmaceutical and the carrier under conditions to provide a respirable dry powder comprising particles wherein 95% of the mass of the composition comprises particles having a particle size below 10 μm.
13. A method for preparing a spray-dried pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of a pharmaceutical and a pharmaceutically acceptable carrier, which method comprises spray drying an aqueous mixture of a pharmaceutical selected from the group consisting of parathyroid hormone, interleukin 1 receptor, heparin, low molecular weight heparin, and calcitonin.
14. The method of claim 12 or 13, wherein the carrier comprises HSA.
15. The method of claim 14, wherein the carrier further comprises a carbohydrate bulking agent.
16. The method of claim 15, wherein the bulking agent is mannitol.
17. The method of claim 12, wherein 80% of the mass of the spray-dry composition has a particle size less than 5 μm.
18. A spray-dried, macromolecule-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of the macromolecule in combination with a pharmaceutically acceptable carrier produced by the method of claims 12-17.
19. Compositions as in claims 1-8, having a moisture content below 10%.
PCT/US1996/005070 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments WO1996032149A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX9707855A MX9707855A (en) 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments.
JP8531213A JPH11503731A (en) 1995-04-14 1996-04-12 Delivery of aerosolized drugs to the lungs
EP96911738A EP0825885B1 (en) 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments
AT96911738T ATE261742T1 (en) 1995-04-14 1996-04-12 PULMONARY ADMINISTRATION OF MEDICATIONS IN AEROSOL FORM
CA002218116A CA2218116C (en) 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments
AU54827/96A AU702150B2 (en) 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments
DE69631881T DE69631881T2 (en) 1995-04-14 1996-04-12 PULMONAL ADMINISTRATION OF MEDICINES IN AEROSOL FORM
US08/733,225 US6258341B1 (en) 1995-04-14 1996-10-17 Stable glassy state powder formulations
US08/950,385 US6309671B1 (en) 1995-04-14 1997-10-14 Stable glassy state powder formulations
US08/951,312 US6019968A (en) 1995-04-14 1997-10-16 Dispersible antibody compositions and methods for their preparation and use
US09/531,183 US6514496B1 (en) 1995-04-14 2000-03-21 Dispersible antibody compositions and methods for their preparation and use
US09/879,853 US6589560B2 (en) 1995-04-14 2001-06-11 Stable glassy state powder formulations
US10/413,016 US20030215512A1 (en) 1995-04-14 2003-04-14 Stable glassy state powder formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/423,515 US6582728B1 (en) 1992-07-08 1995-04-14 Spray drying of macromolecules to produce inhaleable dry powders
US08/423,515 1995-04-14

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US08/423,515 Continuation-In-Part US6582728B1 (en) 1992-07-08 1995-04-14 Spray drying of macromolecules to produce inhaleable dry powders
US08/423,515 Continuation US6582728B1 (en) 1992-07-08 1995-04-14 Spray drying of macromolecules to produce inhaleable dry powders

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08/733,225 Continuation-In-Part US6258341B1 (en) 1995-04-14 1996-10-17 Stable glassy state powder formulations
US08/733,225 Continuation US6258341B1 (en) 1995-04-14 1996-10-17 Stable glassy state powder formulations
US08/951,312 Continuation-In-Part US6019968A (en) 1995-04-14 1997-10-16 Dispersible antibody compositions and methods for their preparation and use

Publications (1)

Publication Number Publication Date
WO1996032149A1 true WO1996032149A1 (en) 1996-10-17

Family

ID=23679173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005070 WO1996032149A1 (en) 1995-04-14 1996-04-12 Pulmonary delivery of aerosolized medicaments

Country Status (11)

Country Link
US (10) US6582728B1 (en)
EP (2) EP0825885B1 (en)
JP (2) JPH11503731A (en)
KR (1) KR100466486B1 (en)
AT (1) ATE261742T1 (en)
AU (1) AU702150B2 (en)
CA (1) CA2218116C (en)
DE (1) DE69631881T2 (en)
ES (1) ES2215191T3 (en)
MX (1) MX9707855A (en)
WO (1) WO1996032149A1 (en)

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016490A1 (en) * 1997-09-26 1999-04-08 1263152 Ontario Inc. Aerosol medication delivery apparatus and system
WO1999055362A1 (en) * 1998-04-29 1999-11-04 Genentech, Inc. Spray dried formulations of igf-i
US6051551A (en) * 1997-10-31 2000-04-18 Eli Lilly And Company Method for administering acylated insulin
WO2000021594A2 (en) 1998-10-09 2000-04-20 Inhale Therapeutic Systems, Inc. Flow resistance modulated aerosolized active agent delivery
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
WO2001013892A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
WO2001024776A1 (en) * 1999-10-01 2001-04-12 Glatt Process Technology Gmbh Biodegradable excipient systems for therapeutically active substances and method for producing the same
WO2001058425A2 (en) * 2000-02-08 2001-08-16 King's College London Pharmaceutical composition for pulmonary delivery
US6293279B1 (en) 1997-09-26 2001-09-25 Trudell Medical International Aerosol medication delivery apparatus and system
JP2001517691A (en) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド Porous fine particles and method of use
WO2001082906A1 (en) * 2000-05-03 2001-11-08 Vectura Limited Powders for use in a dry powder inhaler
US6315983B1 (en) * 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
WO2002032406A2 (en) * 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AU752563B2 (en) * 1998-06-30 2002-09-19 Quadrant Drug Delivery Limited Microparticle formulation for inhalation
EP1254944A1 (en) * 1999-12-24 2002-11-06 Otsuka Pharmaceutical Co., Ltd. Dry compositions containing hydrophobic amino acid
WO2002089916A1 (en) * 2001-05-04 2002-11-14 Pfizer Products Inc. Method of preventing type 2 diabetes with aerosolized insulin
WO2002054868A3 (en) * 2000-12-21 2003-03-27 Inhale Therapeutic Systems, Inc. Pulmonary delivery of polyene antifungal agents
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
WO2003092851A1 (en) * 2002-05-02 2003-11-13 Accentus Plc Preparation of small crystals
US6669960B2 (en) 1999-12-21 2003-12-30 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
EP1342469A3 (en) * 1996-10-17 2004-01-21 Nektar Therapeutics Stable glass state powder formulations
EP1424066A1 (en) * 1995-12-25 2004-06-02 Otsuka Pharmaceutical Co., Ltd. Dry compositions comprising hydrophobic stabilisers
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2005020953A1 (en) * 2003-08-22 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with a low residual moisture and excellent storage stability
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
WO2005058289A1 (en) * 2003-12-16 2005-06-30 Fang Jin A method of preparing intranasal dry powders inhalant of calcitonin
WO2005067898A2 (en) * 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
DE102004022926A1 (en) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powders containing at least one 1,4 O-linked sucrose derivative and process for their preparation
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US7172999B2 (en) 1995-10-25 2007-02-06 Roche Diagnostics Gmbh Method and preparations for stabilizing biological materials by drying methods without freezing
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
EP1797902A2 (en) * 2000-12-29 2007-06-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7326691B2 (en) 2004-06-21 2008-02-05 Nektar Therapeutics Compositions comprising amphotericin B, methods, and systems
US7378438B2 (en) 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7448379B2 (en) 2001-06-15 2008-11-11 Otsuka Pharmaceutical Co., Ltd. Composition, vessel, dry powder inhalation system, and related methods for transpulmonary administration
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US7540284B2 (en) 2001-06-20 2009-06-02 Novartis Pharma Ag Powder aerosolization apparatus and method
US7559325B2 (en) 2003-04-09 2009-07-14 Novartis Pharma Ag Aerosolization apparatus with air inlet shield
EP0871430B2 (en) † 1995-07-24 2009-09-09 Vectura Limited Powders and their use in dry powder inhalers
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
WO2010007604A2 (en) * 2008-07-16 2010-01-21 Royal College Of Surgeons In Ireland Inhalable microparticles, and methods for the production thereof
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
WO2010060875A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
WO2010115032A1 (en) 2009-04-01 2010-10-07 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid p
WO2010138868A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
EP2283896A2 (en) 2001-04-09 2011-02-16 Novartis Vaccines and Diagnostics, Inc. HSA-free formulations of interferon-beta
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
EP2364735A2 (en) 2005-12-16 2011-09-14 Nektar Therapeutics Branched PEG conjugates of GLP-1
US8030038B2 (en) 2008-10-03 2011-10-04 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
USRE43174E1 (en) 2000-04-11 2012-02-14 Trudell Medical International Aerosol delivery apparatus
US8222012B2 (en) 2009-10-01 2012-07-17 E. I. Du Pont De Nemours And Company Perhydrolase for enzymatic peracid production
US8273561B2 (en) 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP2565193A1 (en) 2009-01-23 2013-03-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8501240B2 (en) 1999-10-29 2013-08-06 Novartis Ag Compositions comprising an active agent
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2013151744A1 (en) 2012-04-05 2013-10-10 University Of Florida Research Foundation, Inc. Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US8573197B2 (en) 2006-10-25 2013-11-05 Novartis Ag Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
WO2014164736A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
US8973571B1 (en) 2002-05-02 2015-03-10 Pre Holding, Inc. Aerosol medication inhalation system
US8974828B2 (en) 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP2853268A1 (en) * 2009-01-08 2015-04-01 Mannkind Corporation Treatment of hyperglycemia with GLP-1
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9458103B2 (en) 2012-03-23 2016-10-04 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US9585834B2 (en) 2004-11-23 2017-03-07 Vectura Limited Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9682153B2 (en) 2008-09-19 2017-06-20 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9700689B2 (en) 2002-05-21 2017-07-11 Trudell Medical International Medication delivery apparatus and system and methods for the use and assembly thereof
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9907754B2 (en) 2013-03-28 2018-03-06 Vectura Limited Taurine compositions suitable for inhalation
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
WO2018078186A1 (en) 2016-10-31 2018-05-03 Vectura Limited Inhalable powder composition comprising il-13 antibody
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10039285B2 (en) * 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10207066B2 (en) 2003-04-09 2019-02-19 Bgp Products Operations Gmbh Aerosolization apparatus with capsule puncture alignment guide
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US10441537B2 (en) 2017-05-10 2019-10-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US10660578B2 (en) 2016-02-01 2020-05-26 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
WO2020145872A1 (en) * 2019-01-09 2020-07-16 Ziccum Ab Stabilized non-enveloped virus compositions
US10758506B2 (en) 2014-11-24 2020-09-01 Entrinsic Bioscience, Inc. Amino acid compositions for the treatment of porcine epidemic diarrhea
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
WO2020223237A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
US10940137B2 (en) 2010-09-24 2021-03-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving gastrointestinal function
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022074656A1 (en) 2020-10-07 2022-04-14 Protalix Ltd. Long-acting dnase
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2023283439A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
US11576884B2 (en) 2016-10-04 2023-02-14 University Of Florida Research Foundation, Inc. Amino acid compositions and uses thereof
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
BR9307141A (en) * 1992-09-29 1999-03-30 Inhale Therapeutic Syst Process for the pulsatile sistance release of an active fragment of parathyroid hormone (PTH) to a mammalian host and to a patient and pharmaceutical composition
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
DE69535897D1 (en) * 1994-03-07 2009-01-22 Nektar Therapeutics Method and composition for the pulmonary delivery of insulin
ES2245780T3 (en) * 1994-05-18 2006-01-16 Nektar Therapeutics METHODS AND COMPOSITIONS FOR THE FORMULATION OF INTERFERONS AS A DRY POWDER.
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7779020B2 (en) * 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US7052678B2 (en) * 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
TWI277425B (en) * 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
EP2280020B1 (en) * 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
JP2003507410A (en) * 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Controlled release from dry powder formulations
FI20002217A (en) * 1999-12-30 2001-07-01 Orion Yhtymae Oyj inhalation particles
US6645261B2 (en) * 2000-03-06 2003-11-11 Cargill, Inc. Triacylglycerol-based alternative to paraffin wax
JP4711520B2 (en) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 Bioactive peptide-containing powder
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
EP2060253A1 (en) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1345629A2 (en) * 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6824572B2 (en) 2001-03-06 2004-11-30 Cargill, Incorporated Vegetable oil based wax compositions
US6503285B1 (en) * 2001-05-11 2003-01-07 Cargill, Inc. Triacylglycerol based candle wax
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) * 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
EP1399132A1 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Production of hard, dense particles
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
US7128766B2 (en) * 2001-09-25 2006-10-31 Cargill, Incorporated Triacylglycerol based wax compositions
US20070203333A1 (en) * 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050075304A1 (en) * 2001-11-30 2005-04-07 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
WO2003068007A1 (en) * 2002-02-18 2003-08-21 Ajinomoto Co., Inc. Dry powder holding flavor and aroma components and process for producing the same
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN101898004A (en) * 2002-02-20 2010-12-01 21世纪国际新技术株式会社 The device of drug administration
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
WO2003070023A1 (en) * 2002-02-22 2003-08-28 Ajinomoto Co., Inc. Amino acid powder and process for producing the same
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc Modulation of protein methylation and phosphoprotein phosphate
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
US20040009231A1 (en) * 2002-03-20 2004-01-15 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
AU2003221888B2 (en) * 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
DE10234165B4 (en) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale A method of filling a trench formed in a substrate with an insulating material
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US6797020B2 (en) * 2002-11-12 2004-09-28 Cargill, Incorporated Triacylglycerol based wax for use in container candles
US6773469B2 (en) * 2002-11-12 2004-08-10 Cargill, Incorporated Triacylglycerol based wax for use in candles
CN1745170A (en) * 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 High pressure spray-dry of bioactive materials
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
KR20050088243A (en) * 2002-12-30 2005-09-02 넥타르 테라퓨틱스 Prefilming atomizer
JP2006514954A (en) * 2002-12-31 2006-05-18 ネクター セラピューティクス Antibody-containing particles and compositions
EP1581182A2 (en) * 2002-12-31 2005-10-05 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
MXPA05007158A (en) * 2002-12-31 2005-09-21 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration.
AU2004229427A1 (en) * 2003-04-09 2004-10-28 Nektar Therapeutics Hemophilia treatment by inhalation of coagulation factors
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US7192457B2 (en) * 2003-05-08 2007-03-20 Cargill, Incorporated Wax and wax-based products
US20050172958A1 (en) * 2003-08-20 2005-08-11 The Brigham And Women's Hospital, Inc. Inhalation device and system for the remote monitoring of drug administration
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20050069591A1 (en) * 2003-09-30 2005-03-31 Howard Bernstein Injectable, oral, or topical sustained release pharmaceutical formulations
JP2007517771A (en) * 2003-10-01 2007-07-05 モメンタ ファーマシューティカルズ インコーポレイテッド Polysaccharides for pulmonary delivery of active substances
PT1691825E (en) * 2003-12-11 2011-10-12 Ares Trading Sa Stabilized interferon liquid formulations
JP5183068B2 (en) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ Powder formation by atmospheric spray freeze drying
ES2584867T3 (en) * 2004-01-12 2016-09-29 Mannkind Corporation A method that reduces serum proinsulin levels in type 2 diabetics
CA2554973A1 (en) * 2004-02-10 2005-08-25 Advanced Inhalation Research, Inc. Particles for inhalation rapid release properties
EP2319500B1 (en) * 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP1734938B1 (en) * 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
MXPA06012240A (en) * 2004-04-23 2007-01-31 Cydex Inc Dpi formulation containing sulfoalkyl ether cyclodextrin.
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
EP1747672A4 (en) * 2004-05-19 2010-02-17 Alza Corp Method and formulation for transdermal delivery of immunologically active agents
EP1755720A1 (en) * 2004-05-20 2007-02-28 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
AU2005268972A1 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006076277A1 (en) * 2005-01-10 2006-07-20 Nektar Therapeutics Compositions and methods for increasing the bioavailability of pulmonarily administered insulin
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US8653028B2 (en) * 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
WO2006128025A2 (en) * 2005-05-23 2006-11-30 Children's Hospital Medical Center Regulatory proteins in lung repair and treatment of lung disease
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
US20090192227A1 (en) * 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
US8642543B2 (en) * 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1928525A2 (en) * 2005-09-29 2008-06-11 Nektar Therapeutics Receptacles and kits, such as for dry powder packaging
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
AU2007238114B2 (en) * 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US9222728B2 (en) * 2006-04-24 2015-12-29 Medinstill Development Llc Penetrable and resealable lyophilization device
DE102006030164A1 (en) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative powders
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
CA2898230C (en) 2007-01-10 2018-04-24 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US8342172B2 (en) * 2007-02-05 2013-01-01 The Brigham And Women's Hospital, Inc. Instrumented metered-dose inhaler and methods for predicting disease exacerbations
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP2146711A4 (en) 2007-04-12 2011-10-26 Univ Minnesota Ischemia/reperfusion protection compositions and methods of using
US9554997B2 (en) * 2007-06-18 2017-01-31 New York University Polymer carrier
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
US8268354B2 (en) 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
EP2213282A1 (en) 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CN101878043A (en) * 2007-12-20 2010-11-03 默克雪兰诺有限公司 PEG-interferon-beta formulations
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
EP2265309B1 (en) 2008-03-17 2015-12-16 Discovery Laboratories, Inc. Ventilation circuit adaptor and proximal aerosol delivery system
AU2009246217B2 (en) 2008-05-15 2013-01-10 Novartis Ag Pulmonary delivery of a fluoroquinolone
HUE038339T2 (en) 2008-06-23 2018-10-29 Sun Patent Trust Method of arranging reference signals and wireless communication base station apparatus
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
KR101884616B1 (en) * 2008-10-20 2018-08-06 모레 매트릭스 인코포레이티드 Polypeptide for treating or preventing adhesions
ES2402241T3 (en) 2008-10-22 2013-04-30 Trudell Medical International Modular Spray Supply System
CA2742600A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
WO2010078373A1 (en) 2008-12-29 2010-07-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520685A (en) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR101856462B1 (en) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010111680A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
JP2012521760A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EA201171175A1 (en) 2009-03-27 2012-05-30 Мерк Шарп Энд Домэ Корп. PHK-MEDIATED INTERFERENCE INHIBITING EXPRESSION OF A CELL INTERCEPTIVE ADHESION MOLECULE 1 (ICAM-1) WITH USING A SHORT INTERFERATING NUCLEINIC ACID (IC) -1
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
EP3202399A1 (en) 2009-07-24 2017-08-09 Amazetis SA Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
TWI543763B (en) 2009-12-09 2016-08-01 日東電工股份有限公司 Modulation of hsp47 expression
EP2608769B1 (en) * 2010-08-23 2019-11-06 Fraunhofer Gesellschaft zur Förderung der Angewand Humidified particles comprising a therapeutically active substance
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9332776B1 (en) 2010-09-27 2016-05-10 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
US8939388B1 (en) 2010-09-27 2015-01-27 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
KR101915241B1 (en) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 Monovalent metal cation dry powders for inhalation
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
ES2663009T3 (en) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
ES2645769T3 (en) 2011-01-05 2017-12-07 Hospira, Inc. Vancomycin spray drying
JP6000287B2 (en) 2011-03-03 2016-09-28 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compositions and methods for treating lung disease and injury
AU2012242768B2 (en) 2011-04-12 2017-10-12 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2012148998A1 (en) 2011-04-25 2012-11-01 Cornell University Use of uridine and deoxyuridine to treat folate-responsive pathologies
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
SG195038A1 (en) 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
RU2632888C2 (en) 2011-06-08 2017-10-11 Нитто Денко Корпорейшн Compounds for targeted delivery of medicine and enhanced siphk activity
TWI658830B (en) 2011-06-08 2019-05-11 日東電工股份有限公司 Retinoid-liposomes for enhancing modulation of hsp47 expression
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
PE20191242A1 (en) 2011-10-25 2019-09-16 Prothena Biosciences Ltd ANTIBODY FORMULATIONS AND METHODS
EP2589381B1 (en) 2011-11-04 2016-08-31 Rabindra Tirouvanziam Compositions for improving or preserving lung function in a patient with a pulmonary disorder
RU2615076C2 (en) 2011-12-16 2017-04-03 Новартис Аг Aerosolization device for drug delivery independent on inhalation profile
CN107596518B (en) 2012-02-29 2021-04-23 普马特里克斯营业公司 Inhalable dry powder
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
ES2848025T3 (en) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevention of lung cancer recurrence with lipid-complexed cisplatin
CN104043104B (en) 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2015038644A2 (en) 2013-09-10 2015-03-19 Debrabander Jef Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
RU2694063C2 (en) 2014-07-08 2019-07-09 Эмфастар Фармасьютикалз, Инк. Finely dispersed insulin, finely dispersed insulin analogues and methods for their industrial production
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2018501201A (en) 2014-11-17 2018-01-18 モイライ マトリックス インコーポレイテッド Compositions and methods for preventing or treating diseases, conditions, or processes characterized by abnormal fibroblast proliferation and extracellular matrix deposition
KR20170098861A (en) 2014-12-10 2017-08-30 하이퍼스템 에스에이 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
BR112017014737A2 (en) 2015-01-08 2018-01-16 Moerae Matrix Inc formulation of mk2 inhibitor peptides
CN107847510A (en) 2015-03-11 2018-03-27 辛辛那提大学 For treating the composition and method of bacterium infection
EP3268022A4 (en) 2015-03-12 2018-11-21 Moerae Matrix, Inc., Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
WO2016159889A1 (en) 2015-04-02 2016-10-06 Hill-Rom Services Pte. Ltd. Manifold for respiratory device
WO2016200694A1 (en) 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
CN107949279A (en) 2015-07-06 2018-04-20 得克萨斯系统大学评议会 It can be used as the benzamide or benzamine compound of the anticancer for treating human cancer
CA2991420A1 (en) 2015-07-15 2017-01-19 The Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
US10328216B2 (en) 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
CN110234401B (en) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 Methods and compositions for adaptive immunomodulation
CA3047098A1 (en) 2016-12-16 2018-06-21 Jia Zhou Inhibitors of bromodomain-containing protein 4 (brd4)
US10786449B2 (en) 2017-07-17 2020-09-29 Northriver Pharm, LLC Nasal composition comprising a mucoadhesive polymer
EP3655021B1 (en) 2017-07-19 2023-03-22 Unikeris Limited Adenosine deaminase for treating or ameliorating scleroderma-associated vasculopathy
US9993787B1 (en) 2017-08-04 2018-06-12 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9861945B1 (en) 2017-08-04 2018-01-09 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10155234B1 (en) 2017-08-04 2018-12-18 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
AU2018312095B2 (en) 2017-08-04 2021-10-28 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10486173B2 (en) 2017-08-04 2019-11-26 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
WO2019157200A1 (en) 2018-02-07 2019-08-15 Lovelace Respiratory Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
US11786580B2 (en) 2018-04-23 2023-10-17 Emory University VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease
US10569244B2 (en) 2018-04-28 2020-02-25 ZoomEssence, Inc. Low temperature spray drying of carrier-free compositions
US11389433B2 (en) 2018-06-18 2022-07-19 Board Of Regents, The University Of Texas System BRD4 inhibitor treatment of IgE-mediated diseases
FI3599243T3 (en) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
EP3805243B1 (en) 2019-10-09 2023-11-15 Windtree Therapeutics, Inc. Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US5384133A (en) * 1986-08-11 1995-01-24 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules

Family Cites Families (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1855591A (en) 1926-02-03 1932-04-26 Wallerstein Co Inc Invertase preparation and method of making the same
US2598525A (en) 1950-04-08 1952-05-27 E & J Mfg Co Automatic positive pressure breathing machine
DE1812574U (en) 1960-04-05 1960-06-02 Felix Duerst CONCRETE MIXER.
BE602237A (en) 1960-04-07
US3300474A (en) 1964-02-12 1967-01-24 Pharmacia Ab Sucrose ether copolymerizates
US3362405A (en) 1964-04-06 1968-01-09 Hamilton O. Hazel Method and apparatus for admixing gas with solid particles
BR6570825D0 (en) 1964-07-04 1973-08-16 Shiryo Kogyo Co Inc Nippon PROCESS TO PRODUCE CRYSTALLIZED GRANULES FROM SUGAR AND OTHER CRYSTALLOID SOLUTIONS
US3314803A (en) 1966-01-26 1967-04-18 Gen Foods Corp Mannitol fixed flavor and method of making same
US3674901A (en) * 1966-07-26 1972-07-04 Nat Patent Dev Corp Surgical sutures
US3425600A (en) 1966-08-11 1969-02-04 Abplanalp Robert H Pressurized powder dispensing device
US3554768A (en) 1967-08-01 1971-01-12 Gen Foods Corp Carbohydrate fixed acetaldehyde
US3557717A (en) * 1968-05-17 1971-01-26 Gen Mills Inc Process for making candy floss
FR7461M (en) * 1968-06-19 1970-01-05
US3620776A (en) 1968-06-28 1971-11-16 Nestle Sa Spray drying process
US3555717A (en) * 1968-10-24 1971-01-19 Victor Comptometer Corp Artificial fishing lure
DE1812574A1 (en) 1968-12-04 1970-06-11 Riedel De Haen Ag Process for the production of biocidal granules
US3594476A (en) 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3632357A (en) * 1969-07-29 1972-01-04 Standard Brands Inc Method of producing hard candy
US3655442A (en) * 1969-08-27 1972-04-11 California & Hawaiian Sugar Method of making sugar and sugar products
US3666496A (en) 1969-09-03 1972-05-30 Firmenich Inc Water soluble,powdered,terpene-containing flavors
US3937668A (en) 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
US3764716A (en) 1970-11-16 1973-10-09 American Potato Co Preparation of dehydrated mashed potatoes
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US3971852A (en) 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
GB1479283A (en) 1973-07-23 1977-07-13 Bespak Industries Ltd Inhaler for powdered medicament
FR2257351A1 (en) 1974-01-11 1975-08-08 Obert Jean Claude Aerosol device for solid vaccines - feed and breaker screws deliver material sideways into blower chamber
IT1016489B (en) 1974-03-18 1977-05-30 Isf Spa INHALER
DE2415159A1 (en) 1974-03-29 1975-10-09 Hoechst Ag SPRAY PRODUCTS CONTAINING ALKALINE CANSULFONATE AND METHOD FOR THEIR MANUFACTURING
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
JPS5134879A (en) 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4005711A (en) 1975-01-13 1977-02-01 Syntex Puerto Rico, Inc. Inhalation device
US3964483A (en) 1975-01-13 1976-06-22 Syntex Puerto Rico, Inc. Inhalation device
FR2299011A1 (en) 1975-01-29 1976-08-27 Obert Jean Claude PART AEROSOL GENERATOR
US3991304A (en) 1975-05-19 1976-11-09 Hillsman Dean Respiratory biofeedback and performance evaluation system
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US3994421A (en) 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
US4109019A (en) 1975-11-18 1978-08-22 William Percy Moore Process for improved ruminant feed supplements
NL7800383A (en) * 1977-01-20 1978-07-24 Rhone Poulenc Ind NEW ISOQUEINOLINE DERIVATIVES, THEIR PREPARATION AND PREPARATIONS CONTAINING THE ISOQUEINOLINE DERIVATIVES.
US4180593A (en) 1977-04-29 1979-12-25 Cohan Allan N Process for producing round spherical free flowing blown bead food products of controlled bulk density
US4211769A (en) 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
DE2748132A1 (en) 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
NL7712041A (en) 1977-11-01 1979-05-03 Handelmaatschappij Voorheen Be Suction equipment for powdery material - incorporates ejector type suction pump and cyclone type separator
US4244949A (en) * 1978-04-06 1981-01-13 The Population Council, Inc. Manufacture of long term contraceptive implant
EP0005585B1 (en) 1978-05-03 1981-08-12 FISONS plc Inhalation device
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
SU1003926A1 (en) 1979-01-24 1983-03-15 Всесоюзный Научно-Исследовательский И Конструкторский Институт Автогенного Машиностроения Powder feeder
DE3061384D1 (en) 1979-02-21 1983-01-27 Ici Plc A process for the extraction of poly-3-hydroxy-butyric acid from microbial cells
IT1116047B (en) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti DEVICE FOR THE QUICK INHALATION OF POWDER DRUGS BY PERSONS SUFFERING FROM ASTHMA
JPS6034925B2 (en) 1979-07-31 1985-08-12 帝人株式会社 Long-acting nasal preparation and its manufacturing method
US4446862A (en) 1979-10-30 1984-05-08 Baum Eric A Breath actuated devices for administering powdered medicaments
US4294624A (en) 1980-03-14 1981-10-13 Veltman Preston Leonard Drying co-mingled carbohydrate solution and recycled product by dielectric heating
ZA811942B (en) 1980-03-25 1983-02-23 H Malem Nebulising apparatus
EP0111216A3 (en) 1980-03-31 1985-01-16 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor
CS217203B1 (en) * 1980-06-24 1982-12-31 Vladimir Svaty Device for simmultaneous shot of two wefts in two open sheds
US4423079A (en) 1980-07-14 1983-12-27 Leo Kline Growth promoting compositions for Lactobacillus sanfrancisco and method of preparation
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4371557A (en) * 1981-01-21 1983-02-01 General Foods Corporation Maintenance of protein quality in foods containing reducing sugars
US4327077A (en) * 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4484577A (en) 1981-07-23 1984-11-27 Key Pharmaceuticals, Inc. Drug delivery method and inhalation device therefor
GB2105189B (en) 1981-07-24 1985-03-20 Fisons Plc Inhalation drugs
DE3268533D1 (en) 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
DE3141498A1 (en) 1981-10-20 1983-04-28 Bayer Ag, 5090 Leverkusen Pharmaceutical containing kallikrein and process for its preparation
FR2521565B1 (en) 1982-02-17 1985-07-05 Dior Sa Parfums Christian PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
JPS58154548A (en) 1982-03-09 1983-09-14 Nippon Shinyaku Co Ltd Stabilization of azulene derivative
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4823784A (en) 1982-04-30 1989-04-25 Cadema Medical Products, Inc. Aerosol inhalation apparatus
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
GR79615B (en) 1982-10-08 1984-10-31 Glaxo Group Ltd
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
ES8403520A1 (en) 1983-02-08 1984-03-16 Gandariasbeitia Aguirreche Man Continuous prepn. of proteolytic and amylolytic enzymes
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
JPS6035263A (en) 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd Stabilization of immunologically active substance immobilized on non-soluble carrier and physiologically active substance measuring reagent containing the same as composition unit
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
DE3345722A1 (en) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim INHALATOR
US4534343A (en) 1984-01-27 1985-08-13 Trutek Research, Inc. Metered dose inhaler
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US4820534A (en) 1984-03-19 1989-04-11 General Foods Corporation Fixation of volatiles in extruded glass substrates
US4927763A (en) 1984-03-21 1990-05-22 Chr. Hansen's Laboratory, Inc. Stabilization of dried bacteria extended in particulate carriers
DD238305A3 (en) 1984-04-23 1986-08-20 Maisan Werke Barby Veb PROCESS FOR THE PREPARATION OF D-GLUCOSE AND STAERKEHYDROLYSATES
US4617272A (en) 1984-04-25 1986-10-14 Economics Laboratory, Inc. Enzyme drying process
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4956295A (en) 1984-05-21 1990-09-11 Chr. Hansen's Laboratory, Inc. Stabilization of dried bacteria extended in particulate carriers
JPS60258125A (en) 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc Water-soluble dried material containing proteinic physiologically active substance
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
NZ209900A (en) 1984-10-16 1989-08-29 Univ Auckland Automatic inhaler
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FR2575678B1 (en) 1985-01-04 1988-06-03 Saint Gobain Vitrage PNEUMATIC POWDER EJECTOR
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4942544A (en) 1985-02-19 1990-07-17 Kenneth B. McIntosh Medication clock
US4946828A (en) 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
ATE78158T1 (en) 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
ATE68524T1 (en) 1985-07-09 1991-11-15 Quadrant Bioresources Ltd PROTECTION OF PROTEINS AND THE LIKE.
CH672600A5 (en) 1985-07-30 1989-12-15 Glaxo Group Ltd
US4719762A (en) 1985-11-21 1988-01-19 Toshiba Heating Appliances Co., Ltd. Stored ice detecting device in ice making apparatus
FR2591105B1 (en) 1985-12-11 1989-03-24 Moet Hennessy Rech PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID.
JPS62174094A (en) * 1985-12-16 1987-07-30 Ss Pharmaceut Co Ltd Alpha, alpha-trehalose derivative and production thereof
JPH0710344B2 (en) * 1985-12-26 1995-02-08 株式会社林原生物化学研究所 Method for dehydrating hydrated substance by anhydrous glycosyl fructose
SE453566B (en) 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
US4806343A (en) 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US4897353A (en) 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
US4739754A (en) 1986-05-06 1988-04-26 Shaner William T Suction resistant inhalator
US4790305A (en) 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US4926852B1 (en) 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
US5042975A (en) 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
DE3636669C2 (en) 1986-10-28 2001-08-16 Siemens Ag Arrangement for delivering aerosol to a patient's airways and / or lungs
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JPS63186799A (en) 1987-01-29 1988-08-02 不二製油株式会社 Production of powdery oils and fats
US5089181A (en) * 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
FR2611501B1 (en) * 1987-03-04 1991-12-06 Corbiere Jerome NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ROUTE BASED ON LYSINE ACETYLSALIELYLATE AND PROCESS FOR OBTAINING SAME
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
JP2656944B2 (en) 1987-04-30 1997-09-24 クーパー ラボラトリーズ Aerosolization of protein therapeutics
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
FR2618331B1 (en) * 1987-07-23 1991-10-04 Synthelabo PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF UREMIA
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5139016A (en) * 1987-08-07 1992-08-18 Sorin Biomedica S.P.A. Process and device for aerosol generation for pulmonary ventilation scintigraphy
IT1222509B (en) 1987-08-17 1990-09-05 Miat Spa INSUFFLATOR FOR THE ADMINISTRATION OF DRUGS IN THE FORM OF PRE-DOSED POWDER IN OPERATIONS
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5081228A (en) 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
IT1217890B (en) 1988-06-22 1990-03-30 Chiesi Farma Spa DOSED AEROSOL INHALATION DEVICE
US4919962A (en) 1988-08-12 1990-04-24 General Foods Corporation Coffee flakes and process
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
ATE104867T1 (en) 1988-10-04 1994-05-15 Univ Johns Hopkins INHALATION DEVICE FOR AEROSOLS.
US4984158A (en) 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
GB8824897D0 (en) 1988-10-24 1988-11-30 Ici Plc Biocatalysts
US4931361A (en) 1988-11-18 1990-06-05 California Institute Of Technology Cryoprotective reagents in freeze-drying membranes
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
CA2050905A1 (en) * 1989-02-23 1990-08-24 George R. Felt Therapeutic aerosol formulations
SE466684B (en) 1989-03-07 1992-03-23 Draco Ab DEVICE INHALATOR AND PROCEDURE TO REGISTER WITH THE DEVICE INHALATOR MEDICATION
IT1230313B (en) 1989-07-07 1991-10-18 Somova Spa INHALER FOR CAPSULES MEDICATIONS.
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
IL96486A (en) * 1989-11-28 1995-03-30 Syntex Inc Tricyclic compounds, their preparation and pharmaceutical compositions containing them
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
DE4004904A1 (en) 1990-02-16 1990-09-13 Gerhard Brendel DRUM APPLICATOR
US5036237A (en) * 1990-04-09 1991-07-30 Electric Motors And Specialties, Inc. Shaded pole motor
JPH05963A (en) * 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
IT1246350B (en) * 1990-07-11 1994-11-17 Eurand Int METHOD FOR OBTAINING A RAPID SUSPENSION OF INSOLUBLE DRUGS IN WATER
IT1243344B (en) 1990-07-16 1994-06-10 Promo Pack Sa MULTI-DOSE INHALER FOR POWDER MEDICATIONS
US5037912A (en) 1990-07-26 1991-08-06 The Goodyear Tire & Rubber Company Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
GB9016789D0 (en) 1990-07-31 1990-09-12 Lilly Industries Ltd Medicament administering devices
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5217004A (en) 1990-12-13 1993-06-08 Tenax Corporation Inhalation actuated dispensing apparatus
CA2099245A1 (en) * 1991-02-08 1992-08-09 Stanley M. Goldin Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5099833A (en) 1991-02-19 1992-03-31 Baxter International Inc. High efficiency nebulizer having a flexible reservoir
WO1992014449A1 (en) 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5186164A (en) 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE59107894D1 (en) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Nebulizers, in particular for use in devices for inhalation therapy
GB9106648D0 (en) 1991-03-28 1991-05-15 Rhone Poulenc Rorer Ltd New inhaler
US5295479A (en) 1991-04-15 1994-03-22 Leiras Oy Device intended for measuring a dose of powdered medicament for inhalation
US5206200A (en) 1991-04-22 1993-04-27 W. R. Grace & Co.-Conn. Tin catalysts for hydrolysis of latent amine curing agents
US6681767B1 (en) * 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
JP3230056B2 (en) * 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド Device for forming an aerosolized dose of a drug
US5161524A (en) 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
US5253468A (en) 1991-09-03 1993-10-19 Robert Raymond Crop chopping machine
US6013638A (en) * 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5124162A (en) 1991-11-26 1992-06-23 Kraft General Foods, Inc. Spray-dried fixed flavorants in a carbohydrate substrate and process
US5378720A (en) 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU653279B2 (en) 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
EP0621774B1 (en) * 1992-01-21 1996-12-18 Sri International Improved process for preparing micronized polypeptide drugs
KR100189961B1 (en) * 1992-04-09 1999-06-01 윤종용 Noise elimination apparatus
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
KR100208979B1 (en) * 1992-06-12 1999-07-15 야스이 쇼사꾸 Pharmaceutical preparation for intra-airway administration
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) * 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
JP3277342B2 (en) * 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
BR9307141A (en) * 1992-09-29 1999-03-30 Inhale Therapeutic Syst Process for the pulsatile sistance release of an active fragment of parathyroid hormone (PTH) to a mammalian host and to a patient and pharmaceutical composition
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9314886D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Production of a biological control agent
US5559298A (en) * 1993-10-13 1996-09-24 Kabushiki Kaisha Kawai Gakki Seisakusho Waveform read-out system for an electronic musical instrument
EP0655237A1 (en) 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
DE69535897D1 (en) * 1994-03-07 2009-01-22 Nektar Therapeutics Method and composition for the pulmonary delivery of insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
NZ285324A (en) * 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
ES2245780T3 (en) * 1994-05-18 2006-01-16 Nektar Therapeutics METHODS AND COMPOSITIONS FOR THE FORMULATION OF INTERFERONS AS A DRY POWDER.
US5591453A (en) * 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6136346A (en) * 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6190859B1 (en) * 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US5667806A (en) 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
DE19539574A1 (en) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Preparations and processes for stabilizing biological materials by means of drying processes without freezing
TW403653B (en) 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
EP0913178A1 (en) 1997-11-03 1999-05-06 Boehringer Mannheim Gmbh Process for the manufacture of dry, amorphous products comprising biologically active material by means of convection drying and products obtainable by the process
EP0913177A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
TWI310688B (en) * 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US5384133A (en) * 1986-08-11 1995-01-24 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules

Cited By (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871430B2 (en) † 1995-07-24 2009-09-09 Vectura Limited Powders and their use in dry powder inhalers
US7172999B2 (en) 1995-10-25 2007-02-06 Roche Diagnostics Gmbh Method and preparations for stabilizing biological materials by drying methods without freezing
EP1424066A1 (en) * 1995-12-25 2004-06-02 Otsuka Pharmaceutical Co., Ltd. Dry compositions comprising hydrophobic stabilisers
US6315983B1 (en) * 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
EP1342469A3 (en) * 1996-10-17 2004-01-21 Nektar Therapeutics Stable glass state powder formulations
US6703037B1 (en) 1997-07-18 2004-03-09 Pelias Technologies, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
WO1999016490A1 (en) * 1997-09-26 1999-04-08 1263152 Ontario Inc. Aerosol medication delivery apparatus and system
US6435177B1 (en) 1997-09-26 2002-08-20 Trudell Medical International Aerosol medication delivery apparatus and system
US6293279B1 (en) 1997-09-26 2001-09-25 Trudell Medical International Aerosol medication delivery apparatus and system
US6345617B1 (en) 1997-09-26 2002-02-12 1263152 Ontario Inc. Aerosol medication delivery apparatus and system
JP2001517691A (en) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド Porous fine particles and method of use
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US6051551A (en) * 1997-10-31 2000-04-18 Eli Lilly And Company Method for administering acylated insulin
WO1999055362A1 (en) * 1998-04-29 1999-11-04 Genentech, Inc. Spray dried formulations of igf-i
US6926908B2 (en) 1998-06-30 2005-08-09 Quadrant Drug Delivery Limited Formulation for inhalation
AU752563B2 (en) * 1998-06-30 2002-09-19 Quadrant Drug Delivery Limited Microparticle formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000021594A2 (en) 1998-10-09 2000-04-20 Inhale Therapeutic Systems, Inc. Flow resistance modulated aerosolized active agent delivery
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
WO2001013892A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
WO2001013892A3 (en) * 1999-08-25 2001-06-21 Advanced Inhalation Res Inc Large porous particles by spray-drying
AU768299B2 (en) * 1999-08-25 2003-12-04 Alkermes, Inc. Formulation for spray-drying large porous particles
WO2001024776A1 (en) * 1999-10-01 2001-04-12 Glatt Process Technology Gmbh Biodegradable excipient systems for therapeutically active substances and method for producing the same
US8501240B2 (en) 1999-10-29 2013-08-06 Novartis Ag Compositions comprising an active agent
US6669960B2 (en) 1999-12-21 2003-12-30 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US7125566B2 (en) 1999-12-21 2006-10-24 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
EP1254944A1 (en) * 1999-12-24 2002-11-06 Otsuka Pharmaceutical Co., Ltd. Dry compositions containing hydrophobic amino acid
EP1254944A4 (en) * 1999-12-24 2004-09-08 Otsuka Pharma Co Ltd Dry compositions containing hydrophobic amino acid
WO2001058425A2 (en) * 2000-02-08 2001-08-16 King's College London Pharmaceutical composition for pulmonary delivery
WO2001058425A3 (en) * 2000-02-08 2002-01-31 King S College London Pharmaceutical composition for pulmonary delivery
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
USRE45068E1 (en) 2000-04-11 2014-08-12 Trudell Medical International Aerosol delivery apparatus
USRE43174E1 (en) 2000-04-11 2012-02-14 Trudell Medical International Aerosol delivery apparatus
USRE46050E1 (en) 2000-04-11 2016-07-05 Trudell Medical International Aerosol delivery apparatus
WO2001082906A1 (en) * 2000-05-03 2001-11-08 Vectura Limited Powders for use in a dry powder inhaler
EP2851067A1 (en) 2000-05-10 2015-03-25 Novartis AG Phospholipid-based powders for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US6921528B2 (en) 2000-06-09 2005-07-26 Advanced Inhalation Research, Inc. Highly efficient delivery of a large therapeutic mass aerosol
US7556798B2 (en) 2000-06-09 2009-07-07 Alkermes, Inc. Highly efficient delivery of a large therapeutic mass aerosol
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
WO2002032406A2 (en) * 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002224408B8 (en) * 2000-10-18 2002-04-29 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002032406A3 (en) * 2000-10-18 2002-10-10 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US7709461B2 (en) * 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002054868A3 (en) * 2000-12-21 2003-03-27 Inhale Therapeutic Systems, Inc. Pulmonary delivery of polyene antifungal agents
US7767198B2 (en) 2000-12-21 2010-08-03 Novartis Ag Storage stable powder compositions of interleukin-4 receptor
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US7449201B2 (en) 2000-12-21 2008-11-11 Nektar Therapeutics Storage stable power compositions of interleukin-4 receptor
EP1797902A2 (en) * 2000-12-29 2007-06-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
EP1797902A3 (en) * 2000-12-29 2007-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
EP2283896A2 (en) 2001-04-09 2011-02-16 Novartis Vaccines and Diagnostics, Inc. HSA-free formulations of interferon-beta
EP2283897A2 (en) 2001-04-09 2011-02-16 Novartis Vaccines and Diagnostics, Inc. HSA-free formulations of interferon-beta
WO2002089916A1 (en) * 2001-05-04 2002-11-14 Pfizer Products Inc. Method of preventing type 2 diabetes with aerosolized insulin
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
US7448379B2 (en) 2001-06-15 2008-11-11 Otsuka Pharmaceutical Co., Ltd. Composition, vessel, dry powder inhalation system, and related methods for transpulmonary administration
US7735485B2 (en) 2001-06-15 2010-06-15 Otsuka Pharmaceutical Co., Ltd. Dry powder inhalation system for transpulmonary administration
US8443799B2 (en) 2001-06-15 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Dry powder inhalation system for transpulmonary administration
US8333193B2 (en) 2001-06-15 2012-12-18 Otsuka Pharmaceutical Co., Ltd. Dry powder inhalation system for transpulmonary administration
US7540284B2 (en) 2001-06-20 2009-06-02 Novartis Pharma Ag Powder aerosolization apparatus and method
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
WO2003035051A3 (en) * 2001-10-19 2004-03-11 Inhale Therapeutic Syst The use of proton sequestering agents in drug formulations
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US7378438B2 (en) 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7326294B2 (en) 2002-05-02 2008-02-05 Accentus Plc Preparation of small crystals
US8973571B1 (en) 2002-05-02 2015-03-10 Pre Holding, Inc. Aerosol medication inhalation system
US9308335B2 (en) 2002-05-02 2016-04-12 Pre Holding, Inc. Aerosol medication inhalation system
WO2003092851A1 (en) * 2002-05-02 2003-11-13 Accentus Plc Preparation of small crystals
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US10881816B2 (en) 2002-05-21 2021-01-05 Trudell Medical International Medication delivery apparatus and system and methods for the use and assembly thereof
US9700689B2 (en) 2002-05-21 2017-07-11 Trudell Medical International Medication delivery apparatus and system and methods for the use and assembly thereof
US9814849B2 (en) 2002-05-21 2017-11-14 Trudell Medical International Medication delivery apparatus and system and methods for the use and assembly thereof
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US11484671B2 (en) 2003-04-09 2022-11-01 Bgp Products Operations Gmbh Aerosolization apparatus with capsule puncture alignment guide
USRE47526E1 (en) 2003-04-09 2019-07-23 BGP Products Aerosolization apparatus with air inlet shield
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
US10207066B2 (en) 2003-04-09 2019-02-19 Bgp Products Operations Gmbh Aerosolization apparatus with capsule puncture alignment guide
US8069851B2 (en) 2003-04-09 2011-12-06 Novartis Ag Aeorosolization apparatus with air inlet shield
US7559325B2 (en) 2003-04-09 2009-07-14 Novartis Pharma Ag Aerosolization apparatus with air inlet shield
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
US8668934B2 (en) 2003-05-28 2014-03-11 Novartis Ag Pharmaceutical formulation comprising a water-insoluble active agent
WO2005020953A1 (en) * 2003-08-22 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with a low residual moisture and excellent storage stability
WO2005058289A1 (en) * 2003-12-16 2005-06-30 Fang Jin A method of preparing intranasal dry powders inhalant of calcitonin
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
WO2005067898A3 (en) * 2004-01-07 2009-02-26 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
WO2005067898A2 (en) * 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022926A1 (en) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powders containing at least one 1,4 O-linked sucrose derivative and process for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7326691B2 (en) 2004-06-21 2008-02-05 Nektar Therapeutics Compositions comprising amphotericin B, methods, and systems
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9642800B2 (en) 2004-11-23 2017-05-09 Vectura Limited Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
US9585834B2 (en) 2004-11-23 2017-03-07 Vectura Limited Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US8580919B2 (en) 2005-12-16 2013-11-12 Nektar Therapeutics Polymer conjugates of GLP-1
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
EP2364735A2 (en) 2005-12-16 2011-09-14 Nektar Therapeutics Branched PEG conjugates of GLP-1
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8573197B2 (en) 2006-10-25 2013-11-05 Novartis Ag Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
US10245394B2 (en) 2006-10-25 2019-04-02 Mark Glusker Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
US8273561B2 (en) 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
WO2010007604A2 (en) * 2008-07-16 2010-01-21 Royal College Of Surgeons In Ireland Inhalable microparticles, and methods for the production thereof
WO2010007604A3 (en) * 2008-07-16 2011-02-17 Royal College Of Surgeons In Ireland Inhalable microparticles, and methods for the production thereof
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9682153B2 (en) 2008-09-19 2017-06-20 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8283142B2 (en) 2008-10-03 2012-10-09 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
US8252562B2 (en) 2008-10-03 2012-08-28 E. I. Du Pont De Nemours And Company Enzyme powder comprising spray-dried formulation comprising a CE-7 enzyme
US8334120B2 (en) 2008-10-03 2012-12-18 E. I. Du Pont De Nemours And Company Perhydrolases for enzymatic peracid generation
US8304218B2 (en) 2008-10-03 2012-11-06 E.I. Du Pont De Nemours And Company Enzymatic peracid production using a cosolvent
US8337905B2 (en) 2008-10-03 2012-12-25 E. I. Du Pont De Nemours And Company Multi-component peracid generation system
US8148314B2 (en) 2008-10-03 2012-04-03 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
US8105810B2 (en) 2008-10-03 2012-01-31 E. I. Du Pont De Nemours And Company Method for producing peroxycarboxylic acid
US8030038B2 (en) 2008-10-03 2011-10-04 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
US8445247B2 (en) 2008-10-03 2013-05-21 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
US8367597B2 (en) 2008-10-03 2013-02-05 E. I. Du Pont De Nemours And Company Stabilization of perhydrolases
US8486380B2 (en) 2008-10-03 2013-07-16 E. I. Du Pont De Nemours And Company Enzymatic peracid generation formulation
US8062875B2 (en) 2008-10-03 2011-11-22 E. I. du Pont de Nemous & Company Perhydrolases for enzymatic peracid generation
US8293221B2 (en) 2008-10-03 2012-10-23 E. I. Du Pont De Nemours And Company Enzymatic peracid generation formulation
US8148316B2 (en) 2008-10-03 2012-04-03 E. I Du Pont De Nemours And Company Stabilization of perhydrolases
WO2010060875A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2853268A1 (en) * 2009-01-08 2015-04-01 Mannkind Corporation Treatment of hyperglycemia with GLP-1
EP2565193A1 (en) 2009-01-23 2013-03-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8974828B2 (en) 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3552602A1 (en) 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10045939B2 (en) 2009-03-18 2018-08-14 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3552603A1 (en) 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010115032A1 (en) 2009-04-01 2010-10-07 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid p
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010138868A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
EP3106149A1 (en) 2009-05-29 2016-12-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
EP3111926A1 (en) 2009-05-29 2017-01-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
EP3111927A1 (en) 2009-05-29 2017-01-04 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8222012B2 (en) 2009-10-01 2012-07-17 E. I. Du Pont De Nemours And Company Perhydrolase for enzymatic peracid production
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
US10940137B2 (en) 2010-09-24 2021-03-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving gastrointestinal function
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US9873668B2 (en) 2012-03-23 2018-01-23 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
US9458103B2 (en) 2012-03-23 2016-10-04 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
WO2013151744A1 (en) 2012-04-05 2013-10-10 University Of Florida Research Foundation, Inc. Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
US9308245B2 (en) 2012-04-11 2016-04-12 Life-Science Innovations, Llc Spray dried compositions and methods of use
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US10039285B2 (en) * 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014164736A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
EP3427730A1 (en) 2013-03-11 2019-01-16 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
US10758507B2 (en) 2013-03-11 2020-09-01 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US9907754B2 (en) 2013-03-28 2018-03-06 Vectura Limited Taurine compositions suitable for inhalation
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
US10758506B2 (en) 2014-11-24 2020-09-01 Entrinsic Bioscience, Inc. Amino acid compositions for the treatment of porcine epidemic diarrhea
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
US10660578B2 (en) 2016-02-01 2020-05-26 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
US11576884B2 (en) 2016-10-04 2023-02-14 University Of Florida Research Foundation, Inc. Amino acid compositions and uses thereof
WO2018078186A1 (en) 2016-10-31 2018-05-03 Vectura Limited Inhalable powder composition comprising il-13 antibody
US10441537B2 (en) 2017-05-10 2019-10-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020145872A1 (en) * 2019-01-09 2020-07-16 Ziccum Ab Stabilized non-enveloped virus compositions
WO2020223237A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022074656A1 (en) 2020-10-07 2022-04-14 Protalix Ltd. Long-acting dnase
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
WO2023283438A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023283439A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
EP4197528A1 (en) 2021-07-09 2023-06-21 AstraZeneca Pharmaceuticals LP Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Also Published As

Publication number Publication date
US20020127188A1 (en) 2002-09-12
EP1428524A1 (en) 2004-06-16
US20070122418A1 (en) 2007-05-31
CA2218116C (en) 2009-12-08
US20020117170A1 (en) 2002-08-29
US6797258B2 (en) 2004-09-28
US20070042048A1 (en) 2007-02-22
US20030198601A1 (en) 2003-10-23
ATE261742T1 (en) 2004-04-15
US6582728B1 (en) 2003-06-24
US20030185765A1 (en) 2003-10-02
JP2008163033A (en) 2008-07-17
EP0825885A1 (en) 1998-03-04
DE69631881D1 (en) 2004-04-22
EP0825885A4 (en) 1998-08-26
ES2215191T3 (en) 2004-10-01
CA2218116A1 (en) 1996-10-17
DE69631881T2 (en) 2004-08-19
KR19980703878A (en) 1998-12-05
US6372258B1 (en) 2002-04-16
US7097827B2 (en) 2006-08-29
EP0825885B1 (en) 2004-03-17
AU702150B2 (en) 1999-02-18
JPH11503731A (en) 1999-03-30
US20030129141A1 (en) 2003-07-10
MX9707855A (en) 1998-02-28
US6921527B2 (en) 2005-07-26
US20030068279A1 (en) 2003-04-10
AU5482796A (en) 1996-10-30
KR100466486B1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CA2218116C (en) Pulmonary delivery of aerosolized medicaments
US6509006B1 (en) Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6673335B1 (en) Compositions and methods for the pulmonary delivery of aerosolized medicaments
US8173168B2 (en) Dispersible macromolecule compositions and methods for their preparation and use
US6123936A (en) Methods and compositions for the dry powder formulation of interferons
US6258341B1 (en) Stable glassy state powder formulations
US6309671B1 (en) Stable glassy state powder formulations
AU740760B2 (en) Pulmonary delivery of aerosolized medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

WWE Wipo information: entry into national phase

Ref document number: 08733225

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2218116

Country of ref document: CA

Ref country code: CA

Ref document number: 2218116

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1996 531213

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970707278

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996911738

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996911738

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970707278

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996911738

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970707278

Country of ref document: KR